WO2017175817A1 - 炭酸ガスマイクロバブル混合水の製造方法及び製造器 - Google Patents
炭酸ガスマイクロバブル混合水の製造方法及び製造器 Download PDFInfo
- Publication number
- WO2017175817A1 WO2017175817A1 PCT/JP2017/014317 JP2017014317W WO2017175817A1 WO 2017175817 A1 WO2017175817 A1 WO 2017175817A1 JP 2017014317 W JP2017014317 W JP 2017014317W WO 2017175817 A1 WO2017175817 A1 WO 2017175817A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tablet
- carbon dioxide
- water
- microbubble
- acid
- Prior art date
Links
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title claims abstract description 191
- 238000000034 method Methods 0.000 title abstract description 21
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims abstract description 196
- 239000000460 chlorine Substances 0.000 claims abstract description 96
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims abstract description 95
- 229910052801 chlorine Inorganic materials 0.000 claims abstract description 95
- 238000004519 manufacturing process Methods 0.000 claims abstract description 58
- 150000001875 compounds Chemical class 0.000 claims abstract description 29
- 230000003472 neutralizing effect Effects 0.000 claims abstract description 20
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 claims abstract description 15
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 13
- 239000003826 tablet Substances 0.000 claims description 202
- 239000001569 carbon dioxide Substances 0.000 claims description 97
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 97
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 66
- 238000004090 dissolution Methods 0.000 claims description 48
- 150000007524 organic acids Chemical class 0.000 claims description 48
- 238000003287 bathing Methods 0.000 claims description 47
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims description 44
- 239000000203 mixture Substances 0.000 claims description 31
- 229920001223 polyethylene glycol Polymers 0.000 claims description 27
- -1 alkane sulfonate Chemical class 0.000 claims description 24
- 239000003795 chemical substances by application Substances 0.000 claims description 24
- 239000013040 bath agent Substances 0.000 claims description 17
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 16
- 229960005070 ascorbic acid Drugs 0.000 claims description 16
- 235000010350 erythorbic acid Nutrition 0.000 claims description 14
- 125000004432 carbon atom Chemical group C* 0.000 claims description 12
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims description 12
- 239000002211 L-ascorbic acid Substances 0.000 claims description 10
- 235000000069 L-ascorbic acid Nutrition 0.000 claims description 10
- 229930006000 Sucrose Natural products 0.000 claims description 9
- 239000005720 sucrose Substances 0.000 claims description 9
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 8
- CIWBSHSKHKDKBQ-DUZGATOHSA-N D-araboascorbic acid Natural products OC[C@@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-DUZGATOHSA-N 0.000 claims description 8
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 8
- 239000012190 activator Substances 0.000 claims description 8
- 150000001335 aliphatic alkanes Chemical group 0.000 claims description 8
- 239000004318 erythorbic acid Substances 0.000 claims description 8
- 229940026239 isoascorbic acid Drugs 0.000 claims description 8
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 8
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 8
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 claims description 8
- 229910052938 sodium sulfate Inorganic materials 0.000 claims description 8
- 235000011152 sodium sulphate Nutrition 0.000 claims description 8
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 7
- 239000000194 fatty acid Substances 0.000 claims description 7
- 229930195729 fatty acid Natural products 0.000 claims description 7
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 claims description 6
- 229940026231 erythorbate Drugs 0.000 claims description 6
- DHCDFWKWKRSZHF-UHFFFAOYSA-N sulfurothioic S-acid Chemical compound OS(O)(=O)=S DHCDFWKWKRSZHF-UHFFFAOYSA-N 0.000 claims description 6
- 239000002202 Polyethylene glycol Substances 0.000 claims description 5
- 239000012780 transparent material Substances 0.000 claims description 5
- 229940072930 c18 olefin sulfonate Drugs 0.000 claims description 4
- 238000007599 discharging Methods 0.000 claims description 4
- 239000007932 molded tablet Substances 0.000 claims description 4
- 239000008399 tap water Substances 0.000 abstract description 29
- 235000020679 tap water Nutrition 0.000 abstract description 29
- 238000002360 preparation method Methods 0.000 abstract description 5
- 239000003788 bath preparation Substances 0.000 abstract description 4
- 230000005587 bubbling Effects 0.000 abstract description 2
- 235000011089 carbon dioxide Nutrition 0.000 abstract 2
- 230000000694 effects Effects 0.000 description 80
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 39
- 238000011156 evaluation Methods 0.000 description 38
- 239000000047 product Substances 0.000 description 30
- 239000007789 gas Substances 0.000 description 29
- 230000017531 blood circulation Effects 0.000 description 28
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 26
- 238000006386 neutralization reaction Methods 0.000 description 23
- 210000003491 skin Anatomy 0.000 description 22
- 238000002474 experimental method Methods 0.000 description 20
- 238000006243 chemical reaction Methods 0.000 description 19
- 238000005187 foaming Methods 0.000 description 19
- 210000004209 hair Anatomy 0.000 description 14
- 229910052500 inorganic mineral Inorganic materials 0.000 description 14
- 235000010755 mineral Nutrition 0.000 description 14
- 239000011707 mineral Substances 0.000 description 14
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 14
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 13
- 230000002829 reductive effect Effects 0.000 description 13
- 239000011734 sodium Substances 0.000 description 13
- 229910052708 sodium Inorganic materials 0.000 description 13
- 229940083542 sodium Drugs 0.000 description 13
- 235000015424 sodium Nutrition 0.000 description 13
- 235000017557 sodium bicarbonate Nutrition 0.000 description 13
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 13
- 229960004106 citric acid Drugs 0.000 description 11
- 239000008187 granular material Substances 0.000 description 11
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 11
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 10
- 238000005259 measurement Methods 0.000 description 10
- 235000010323 ascorbic acid Nutrition 0.000 description 9
- 239000011668 ascorbic acid Substances 0.000 description 9
- 238000005469 granulation Methods 0.000 description 9
- 230000003179 granulation Effects 0.000 description 9
- 230000004622 sleep time Effects 0.000 description 9
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 8
- 238000002156 mixing Methods 0.000 description 8
- 230000007935 neutral effect Effects 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 238000000748 compression moulding Methods 0.000 description 7
- 238000010586 diagram Methods 0.000 description 7
- 239000006260 foam Substances 0.000 description 7
- 235000010265 sodium sulphite Nutrition 0.000 description 7
- 235000019345 sodium thiosulphate Nutrition 0.000 description 7
- FWVCSXWHVOOTFJ-UHFFFAOYSA-N 1-(2-chloroethylsulfanyl)-2-[2-(2-chloroethylsulfanyl)ethoxy]ethane Chemical compound ClCCSCCOCCSCCCl FWVCSXWHVOOTFJ-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 238000011068 loading method Methods 0.000 description 6
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 6
- 239000011755 sodium-L-ascorbate Substances 0.000 description 6
- 235000019187 sodium-L-ascorbate Nutrition 0.000 description 6
- RUTSRVMUIGMTHJ-UHFFFAOYSA-M sodium;tetradec-1-ene-1-sulfonate Chemical compound [Na+].CCCCCCCCCCCCC=CS([O-])(=O)=O RUTSRVMUIGMTHJ-UHFFFAOYSA-M 0.000 description 6
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 6
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 5
- 239000008118 PEG 6000 Substances 0.000 description 5
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 5
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000001630 malic acid Substances 0.000 description 5
- 235000011090 malic acid Nutrition 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- HRQDCDQDOPSGBR-UHFFFAOYSA-M sodium;octane-1-sulfonate Chemical compound [Na+].CCCCCCCCS([O-])(=O)=O HRQDCDQDOPSGBR-UHFFFAOYSA-M 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 150000001336 alkenes Chemical class 0.000 description 4
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 4
- 238000004140 cleaning Methods 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 239000001530 fumaric acid Substances 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 210000002374 sebum Anatomy 0.000 description 4
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 4
- 229960005055 sodium ascorbate Drugs 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- 102000011782 Keratins Human genes 0.000 description 3
- 108010076876 Keratins Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 150000008064 anhydrides Chemical class 0.000 description 3
- 229960004543 anhydrous citric acid Drugs 0.000 description 3
- 229940072107 ascorbate Drugs 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 230000036760 body temperature Effects 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 229940093915 gynecological organic acid Drugs 0.000 description 3
- 210000003780 hair follicle Anatomy 0.000 description 3
- 238000000465 moulding Methods 0.000 description 3
- WLGDAKIJYPIYLR-UHFFFAOYSA-M octane-1-sulfonate Chemical compound CCCCCCCCS([O-])(=O)=O WLGDAKIJYPIYLR-UHFFFAOYSA-M 0.000 description 3
- 235000005985 organic acids Nutrition 0.000 description 3
- 239000003002 pH adjusting agent Substances 0.000 description 3
- 210000005037 parasympathetic nerve Anatomy 0.000 description 3
- 239000012466 permeate Substances 0.000 description 3
- 238000006479 redox reaction Methods 0.000 description 3
- 235000010378 sodium ascorbate Nutrition 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 235000017550 sodium carbonate Nutrition 0.000 description 3
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 210000003371 toe Anatomy 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 230000002087 whitening effect Effects 0.000 description 3
- UXKQNCDDHDBAPD-UHFFFAOYSA-N 4-n,4-n-diphenylbenzene-1,4-diamine Chemical compound C1=CC(N)=CC=C1N(C=1C=CC=CC=1)C1=CC=CC=C1 UXKQNCDDHDBAPD-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 239000005708 Sodium hypochlorite Substances 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 239000000645 desinfectant Substances 0.000 description 2
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 2
- OSVXSBDYLRYLIG-UHFFFAOYSA-N dioxidochlorine(.) Chemical compound O=Cl=O OSVXSBDYLRYLIG-UHFFFAOYSA-N 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 210000002683 foot Anatomy 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000010907 mechanical stirring Methods 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 235000015497 potassium bicarbonate Nutrition 0.000 description 2
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 2
- 239000011736 potassium bicarbonate Substances 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 235000011181 potassium carbonates Nutrition 0.000 description 2
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 210000004761 scalp Anatomy 0.000 description 2
- 230000007958 sleep Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- 239000004320 sodium erythorbate Chemical group 0.000 description 2
- 235000010352 sodium erythorbate Nutrition 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000001433 sodium tartrate Substances 0.000 description 2
- 229960002167 sodium tartrate Drugs 0.000 description 2
- RBWSWDPRDBEWCR-RKJRWTFHSA-N sodium;(2r)-2-[(2r)-3,4-dihydroxy-5-oxo-2h-furan-2-yl]-2-hydroxyethanolate Chemical group [Na+].[O-]C[C@@H](O)[C@H]1OC(=O)C(O)=C1O RBWSWDPRDBEWCR-RKJRWTFHSA-N 0.000 description 2
- REFMEZARFCPESH-UHFFFAOYSA-M sodium;heptane-1-sulfonate Chemical compound [Na+].CCCCCCCS([O-])(=O)=O REFMEZARFCPESH-UHFFFAOYSA-M 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 230000002889 sympathetic effect Effects 0.000 description 2
- KMIOJWCYOHBUJS-HAKPAVFJSA-N vorolanib Chemical compound C1N(C(=O)N(C)C)CC[C@@H]1NC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C KMIOJWCYOHBUJS-HAKPAVFJSA-N 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- BIIBYWQGRFWQKM-JVVROLKMSA-N (2S)-N-[4-(cyclopropylamino)-3,4-dioxo-1-[(3S)-2-oxopyrrolidin-3-yl]butan-2-yl]-2-[[(E)-3-(2,4-dichlorophenyl)prop-2-enoyl]amino]-4,4-dimethylpentanamide Chemical compound CC(C)(C)C[C@@H](C(NC(C[C@H](CCN1)C1=O)C(C(NC1CC1)=O)=O)=O)NC(/C=C/C(C=CC(Cl)=C1)=C1Cl)=O BIIBYWQGRFWQKM-JVVROLKMSA-N 0.000 description 1
- QIVUCLWGARAQIO-OLIXTKCUSA-N (3s)-n-[(3s,5s,6r)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)piperidin-3-yl]-2-oxospiro[1h-pyrrolo[2,3-b]pyridine-3,6'-5,7-dihydrocyclopenta[b]pyridine]-3'-carboxamide Chemical compound C1([C@H]2[C@H](N(C(=O)[C@@H](NC(=O)C=3C=C4C[C@]5(CC4=NC=3)C3=CC=CN=C3NC5=O)C2)CC(F)(F)F)C)=C(F)C=CC(F)=C1F QIVUCLWGARAQIO-OLIXTKCUSA-N 0.000 description 1
- AEQDJSLRWYMAQI-UHFFFAOYSA-N 2,3,9,10-tetramethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline Chemical compound C1CN2CC(C(=C(OC)C=C3)OC)=C3CC2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- UXHQLGLGLZKHTC-CUNXSJBXSA-N 4-[(3s,3ar)-3-cyclopentyl-7-(4-hydroxypiperidine-1-carbonyl)-3,3a,4,5-tetrahydropyrazolo[3,4-f]quinolin-2-yl]-2-chlorobenzonitrile Chemical compound C1CC(O)CCN1C(=O)C1=CC=C(C=2[C@@H]([C@H](C3CCCC3)N(N=2)C=2C=C(Cl)C(C#N)=CC=2)CC2)C2=N1 UXHQLGLGLZKHTC-CUNXSJBXSA-N 0.000 description 1
- HFGHRUCCKVYFKL-UHFFFAOYSA-N 4-ethoxy-2-piperazin-1-yl-7-pyridin-4-yl-5h-pyrimido[5,4-b]indole Chemical compound C1=C2NC=3C(OCC)=NC(N4CCNCC4)=NC=3C2=CC=C1C1=CC=NC=C1 HFGHRUCCKVYFKL-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 239000004155 Chlorine dioxide Substances 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 241000630665 Hada Species 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 239000004260 Potassium ascorbate Substances 0.000 description 1
- HLCFGWHYROZGBI-JJKGCWMISA-M Potassium gluconate Chemical compound [K+].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O HLCFGWHYROZGBI-JJKGCWMISA-M 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- GCSPRLPXTPMSTL-IBDNADADSA-N [(2s,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)O[C@@]1([C@]2(CO)[C@H]([C@H](O)[C@@H](CO)O2)O)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GCSPRLPXTPMSTL-IBDNADADSA-N 0.000 description 1
- QGHHJZPONFYJRZ-UHFFFAOYSA-K [Na+].[Mg+2].OS([O-])(=O)=O.[O-]S([O-])(=O)=O Chemical compound [Na+].[Mg+2].OS([O-])(=O)=O.[O-]S([O-])(=O)=O QGHHJZPONFYJRZ-UHFFFAOYSA-K 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 238000009360 aquaculture Methods 0.000 description 1
- 244000144974 aquaculture Species 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 210000000467 autonomic pathway Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000010376 calcium ascorbate Nutrition 0.000 description 1
- 229940047036 calcium ascorbate Drugs 0.000 description 1
- 239000011692 calcium ascorbate Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- BLORRZQTHNGFTI-ZZMNMWMASA-L calcium-L-ascorbate Chemical compound [Ca+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] BLORRZQTHNGFTI-ZZMNMWMASA-L 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 150000001765 catechin Chemical class 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 150000001768 cations Chemical group 0.000 description 1
- 235000019398 chlorine dioxide Nutrition 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 239000011362 coarse particle Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001877 deodorizing effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000002526 disodium citrate Substances 0.000 description 1
- 235000019262 disodium citrate Nutrition 0.000 description 1
- CEYULKASIQJZGP-UHFFFAOYSA-L disodium;2-(carboxymethyl)-2-hydroxybutanedioate Chemical compound [Na+].[Na+].[O-]C(=O)CC(O)(C(=O)O)CC([O-])=O CEYULKASIQJZGP-UHFFFAOYSA-L 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000007542 hardness measurement Methods 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 230000002363 herbicidal effect Effects 0.000 description 1
- 238000011086 high cleaning Methods 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000002706 hydrostatic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 235000012245 magnesium oxide Nutrition 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- HWPKGOGLCKPRLZ-UHFFFAOYSA-M monosodium citrate Chemical compound [Na+].OC(=O)CC(O)(C([O-])=O)CC(O)=O HWPKGOGLCKPRLZ-UHFFFAOYSA-M 0.000 description 1
- 239000002524 monosodium citrate Substances 0.000 description 1
- 235000018342 monosodium citrate Nutrition 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- AYOOGWWGECJQPI-NSHDSACASA-N n-[(1s)-1-(5-fluoropyrimidin-2-yl)ethyl]-3-(3-propan-2-yloxy-1h-pyrazol-5-yl)imidazo[4,5-b]pyridin-5-amine Chemical compound N1C(OC(C)C)=CC(N2C3=NC(N[C@@H](C)C=4N=CC(F)=CN=4)=CC=C3N=C2)=N1 AYOOGWWGECJQPI-NSHDSACASA-N 0.000 description 1
- VOVZXURTCKPRDQ-CQSZACIVSA-N n-[4-[chloro(difluoro)methoxy]phenyl]-6-[(3r)-3-hydroxypyrrolidin-1-yl]-5-(1h-pyrazol-5-yl)pyridine-3-carboxamide Chemical compound C1[C@H](O)CCN1C1=NC=C(C(=O)NC=2C=CC(OC(F)(F)Cl)=CC=2)C=C1C1=CC=NN1 VOVZXURTCKPRDQ-CQSZACIVSA-N 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- WLGDAKIJYPIYLR-UHFFFAOYSA-N octane-1-sulfonic acid Chemical compound CCCCCCCCS(O)(=O)=O WLGDAKIJYPIYLR-UHFFFAOYSA-N 0.000 description 1
- XULSCZPZVQIMFM-IPZQJPLYSA-N odevixibat Chemical compound C12=CC(SC)=C(OCC(=O)N[C@@H](C(=O)N[C@@H](CC)C(O)=O)C=3C=CC(O)=CC=3)C=C2S(=O)(=O)NC(CCCC)(CCCC)CN1C1=CC=CC=C1 XULSCZPZVQIMFM-IPZQJPLYSA-N 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 235000019275 potassium ascorbate Nutrition 0.000 description 1
- 229940017794 potassium ascorbate Drugs 0.000 description 1
- 229940093956 potassium carbonate Drugs 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000004224 potassium gluconate Substances 0.000 description 1
- 235000013926 potassium gluconate Nutrition 0.000 description 1
- 229960003189 potassium gluconate Drugs 0.000 description 1
- 229940086066 potassium hydrogencarbonate Drugs 0.000 description 1
- RWPGFSMJFRPDDP-UHFFFAOYSA-L potassium metabisulfite Chemical compound [K+].[K+].[O-]S(=O)S([O-])(=O)=O RWPGFSMJFRPDDP-UHFFFAOYSA-L 0.000 description 1
- 235000010263 potassium metabisulphite Nutrition 0.000 description 1
- CONVKSGEGAVTMB-RXSVEWSESA-M potassium-L-ascorbate Chemical compound [K+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] CONVKSGEGAVTMB-RXSVEWSESA-M 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 230000037384 skin absorption Effects 0.000 description 1
- 231100000274 skin absorption Toxicity 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 230000036558 skin tension Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 239000000176 sodium gluconate Substances 0.000 description 1
- 235000012207 sodium gluconate Nutrition 0.000 description 1
- 229940005574 sodium gluconate Drugs 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 239000001394 sodium malate Substances 0.000 description 1
- ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 description 1
- 229940001482 sodium sulfite Drugs 0.000 description 1
- DAJSVUQLFFJUSX-UHFFFAOYSA-M sodium;dodecane-1-sulfonate Chemical compound [Na+].CCCCCCCCCCCCS([O-])(=O)=O DAJSVUQLFFJUSX-UHFFFAOYSA-M 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000000271 synthetic detergent Substances 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- 239000000057 synthetic resin Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000001931 thermography Methods 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 150000003735 xanthophylls Chemical class 0.000 description 1
- 235000008210 xanthophylls Nutrition 0.000 description 1
Images
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
- B01F23/00—Mixing according to the phases to be mixed, e.g. dispersing or emulsifying
- B01F23/20—Mixing gases with liquids
- B01F23/23—Mixing gases with liquids by introducing gases into liquid media, e.g. for producing aerated liquids
- B01F23/231—Mixing gases with liquids by introducing gases into liquid media, e.g. for producing aerated liquids by bubbling
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
- B01F23/00—Mixing according to the phases to be mixed, e.g. dispersing or emulsifying
- B01F23/20—Mixing gases with liquids
- B01F23/23—Mixing gases with liquids by introducing gases into liquid media, e.g. for producing aerated liquids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0204—Specific forms not provided for by any of groups A61K8/0208 - A61K8/14
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/046—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/23—Sulfur; Selenium; Tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/362—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
- A61K8/463—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur containing sulfuric acid derivatives, e.g. sodium lauryl sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
- A61K8/466—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur containing sulfonic acid derivatives; Salts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/676—Ascorbic acid, i.e. vitamin C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/86—Polyethers
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
- B01F21/00—Dissolving
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
- B01F21/00—Dissolving
- B01F21/30—Workflow diagrams or layout of plants, e.g. flow charts; Details of workflow diagrams or layout of plants, e.g. controlling means
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
- B01F23/00—Mixing according to the phases to be mixed, e.g. dispersing or emulsifying
- B01F23/20—Mixing gases with liquids
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
- B01F23/00—Mixing according to the phases to be mixed, e.g. dispersing or emulsifying
- B01F23/20—Mixing gases with liquids
- B01F23/23—Mixing gases with liquids by introducing gases into liquid media, e.g. for producing aerated liquids
- B01F23/232—Mixing gases with liquids by introducing gases into liquid media, e.g. for producing aerated liquids using flow-mixing means for introducing the gases, e.g. baffles
- B01F23/2323—Mixing gases with liquids by introducing gases into liquid media, e.g. for producing aerated liquids using flow-mixing means for introducing the gases, e.g. baffles by circulating the flow in guiding constructions or conduits
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
- B01F23/00—Mixing according to the phases to be mixed, e.g. dispersing or emulsifying
- B01F23/20—Mixing gases with liquids
- B01F23/23—Mixing gases with liquids by introducing gases into liquid media, e.g. for producing aerated liquids
- B01F23/237—Mixing gases with liquids by introducing gases into liquid media, e.g. for producing aerated liquids characterised by the physical or chemical properties of gases or vapours introduced in the liquid media
- B01F23/2376—Mixing gases with liquids by introducing gases into liquid media, e.g. for producing aerated liquids characterised by the physical or chemical properties of gases or vapours introduced in the liquid media characterised by the gas being introduced
- B01F23/23762—Carbon dioxide
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
- B01F25/00—Flow mixers; Mixers for falling materials, e.g. solid particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
- A61K2800/22—Gas releasing
- A61K2800/222—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/10—Washing or bathing preparations
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
- B01F23/00—Mixing according to the phases to be mixed, e.g. dispersing or emulsifying
- B01F23/20—Mixing gases with liquids
- B01F23/23—Mixing gases with liquids by introducing gases into liquid media, e.g. for producing aerated liquids
- B01F23/237—Mixing gases with liquids by introducing gases into liquid media, e.g. for producing aerated liquids characterised by the physical or chemical properties of gases or vapours introduced in the liquid media
- B01F23/2373—Mixing gases with liquids by introducing gases into liquid media, e.g. for producing aerated liquids characterised by the physical or chemical properties of gases or vapours introduced in the liquid media for obtaining fine bubbles, i.e. bubbles with a size below 100 µm
Definitions
- the present invention relates to a method for producing carbon dioxide microbubble mixed water that significantly improves the blood flow enhancement effect of the carbonated spring bath agent and also has a high carbon dioxide microbubble effect, and a production device that can easily obtain the carbon dioxide microbubble mixed water.
- a foamable composition is a cleaning agent, a bath agent, It is applied to products such as bath water cleaners and pool disinfectants.
- These products (solids) have the advantage of quickly dissolving while generating carbon dioxide when they react with water, and at the same time increase the commercial value because they give consumers a comfortable feeling of use.
- a bath preparation sometimes referred to as a bath preparation
- the blood circulation promoting effect of the generated carbon dioxide gas is actively and widely used.
- microbubbles having a diameter of 0.05 mm or less are said to have high cleaning ability in shower equipment and the like and have been widely used.
- microbubbles are generated in closed water areas such as lakes and aquaculture ponds, it is possible to promote the effect of promoting the dissolution of oxygen in water and the promotion of gas dissolution in water. It has been.
- Patent Document 2 A combination of a technique for dissolving the above carbon dioxide generating component in hot water and a technique for generating microbubbles to purify and sterilize the liquid is also known (see, for example, Patent Document 2).
- Patent Document 1 The technique of Patent Document 1 is provided with a structure in which a carbon dioxide generator such as various bathing agents is disposed in a gas-liquid mixing apparatus as a gas generator, and the discharge port side of the gas-liquid mixing apparatus is connected to a shower head. It is a technique that can be expected to have a health promotion effect such as a cleaning effect and blood circulation promotion by discharging hot water mixed with ingredients and microbubbles from a shower head.
- a health promotion effect such as a cleaning effect and blood circulation promotion by discharging hot water mixed with ingredients and microbubbles from a shower head.
- the conventional bath agent components and tablets dissolve quickly due to dissolution by flowing water under tap water pressure, and the dissolution duration time of the carbon dioxide generating bath agent is extremely short, and the foam is foamed.
- the diameter of the body is extremely large, and even if it touches the body, it does not easily act on the skin or blood vessels.
- the hot water discharged from the shower head flows down quickly after touching the body. Therefore, compared with the case of bathing in the hot water in the bathtub, the contact time between the body and the hot water is short and the contact area is small.
- the bathing agent having a short dissolution duration and the hot bath effect are small and fatal, and the inventors have solved the problems with many patented technologies (see Patent Document 4).
- the present inventors have found that the blood flow-enhancing warm bath effect of the carbon dioxide bath agent or bicarbonate ion bath agent is significantly suppressed by the presence of chlorine in tap water. Disinfectants such as chlorine in tap water can percutaneously absorb the sympathetic nerves of the autonomic nerves, and as a result, cortisol is secreted from the adrenal cortex, causing blood vessels to contract and reducing blood flow. It turns out that there is.
- Patent Document 3 “inorganic reducing substances such as sodium thiosulfate, sodium sulfite, and potassium pyrosulfite, organic reducing substances such as ascorbic acid and sodium ascorbate, catechins, Various kinds of plants such as polyphenols, flavonoids, lycopene, anthocyanins, xanthophylls and bathing agents containing herbicidal reducing substances have been proposed, and this document contains them in tap water when dissolved in tap water.
- the bathing agent described in the above-mentioned document is a tablet, the present inventors have described that the reducing compound is obtained by wetting the tablet into tap water.
- microbubble generation system of the invention is not an effective method for exhibiting a high blood flow promoting warm bath effect.
- Acidic foaming carbon dioxide bathing agent is mainly composed of carbon dioxide gas, so it is hardly taken into blood vessels at neutral pH, and the warm bathing effect is not so much, but neutral pH bicarbonate ion releasing bathing agent
- carbon dioxide gas foaming is unlikely to occur at neutral pH, but by using a combination of bicarbonate and organic acid by a special granulation method, even if the pH is neutral, it reacts violently.
- Carbon dioxide gas is foamed, and high-concentration bicarbonate ions are dissociated by the neutralization reaction, and a large amount of bicarbonate ions are dissolved in the hot water, so that a high warm bath effect can be exhibited.
- it has been clarified through experiments by the present inventors that if a large amount of residual chlorine ions are present in the hot water, the blood flow enhancement effect is greatly suppressed.
- the chlorine removal reaction is very slow and a reaction time of several tens of minutes to several hours is required.
- a reductive compound such as ascorbic acid or ascorbate, such as vitamin C, or sodium thiosulfate, which is conventionally known, when water hits the body immediately after the occurrence of carbon dioxide microbubbles, such as shower hot water Is necessary.
- the chlorine neutralizing ability is maintained and maintained from the moment when the tablet begins to dissolve until the end of dissolution, that is, the last strip after the tablet is used. Therefore, the development of improved technology for this purpose is strongly desired.
- the present invention has been made to solve the above-described problems, and a first object of the present invention is to provide chlorine dioxide contained in tap water in which a carbon dioxide foaming preparation to be put into a microbubble generator is contained as compared with a conventional tablet. From the time when the tablet starts to dissolve in the microbubble generator until the time when the tablet finishes dissolving, it is realized that it is a tablet that maintains the ability to completely neutralize and manufacture carbon dioxide microbubbles using that tablet It is to provide as a method and a manufacturing device.
- the second object of the present invention is that when a tablet starts to dissolve and carbon dioxide gas is generated, a finer foam is continuously generated stably and for a long time, and at the same time chlorine starts to dissolve the tablet.
- a finer foam is continuously generated stably and for a long time, and at the same time chlorine starts to dissolve the tablet.
- the body is exposed to the highest concentration of bicarbonate ion in the neutralization reaction of carbon dioxide gas into water in a chlorine-free hot water, and chlorine is completely removed.
- vasodilation predominates in parasympathetic nerve, blood flow is maximized, and a warm bath effect is maximized. is there.
- the present invention for solving the above problems has the following configuration.
- the carbonic acid bath contained in the microbubble generating part is a method for producing carbon dioxide microbubble mixed water, which is a compression-molded tablet compression-molded in the presence of bicarbonate, organic acid and polyethylene glycol.
- the carbonated bath agent has a tablet diameter and a tablet thickness of 7 mm or more, a tablet hardness of 15 kg or more, a tablet friability of 10 wt% or less, and a pH immediately after dissolving the tablet in hot water is 5.5 to 9.0. Tablets,
- the carbonic acid bathing agent contains at least one of the following excipients and at least one of the following chlorine neutralizing compounds.
- the carbonic acid bathing agent contained in the microbubble generator is a carbon dioxide gas microbubble mixed water producing apparatus that is a compression-molded tablet compression-molded in the presence of bicarbonate, organic acid and polyethylene glycol.
- the carbonated bath agent has a tablet diameter and a tablet thickness of 7 mm or more, a tablet hardness of 15 kg or more, a tablet friability of 10 wt% or less, and a pH immediately after dissolving the tablet in hot water is 5.5 to 9.0. Tablets,
- the carbonic acid bathing agent contains at least one of the following excipients and at least one of the following chlorine neutralizing compounds.
- the activator is an alkane sulfonate having 6 to 18 carbon atoms and an olefin sulfonate having 6 to 18 carbon atoms, and the carbon dioxide microbubble mixed water according to the invention 5, 6 or 7 Manufacturing device.
- the carbon dioxide microbubble mixed water manufacturing apparatus has a shower head part and a shower body part of an integrated configuration or a combined configuration, The production position of the carbon dioxide microbubble mixed water according to any one of the inventions 5 to 8, wherein the carbon dioxide microbubble generating portion is disposed at any one of the following (1) to (6): vessel.
- (1) Configuration disposed in the shower head (2) Configuration disposed in the shower body (3) Between the shower head and the shower body or between the shower head and the shower body (4) Structure arranged at the terminal end of a water supply hose connected to the shower body (5) Water supply hose connected to the shower body (6) Configuration arranged in the middle of the water supply hose connected to the shower body
- invention 10 10. The carbon dioxide microbubble mixed water producing device according to any one of the fifth to ninth aspects, wherein the carbon dioxide microbubble generator is an attachment type that can be easily attached and detached in a one-touch manner.
- the carbon dioxide microbubble generation part is formed of a transparent material, and the dissolution state of the carbonated bath tablet contained in the carbon dioxide microbubble generation part and the presence or absence of the tablet are visible from the outside.
- At least a part of the carbon dioxide microbubble mixed water producing device and at least a part of the members constituting the water passage inside thereof are formed of a transparent material, and the hot water flowing in the water passage can be visually observed from the outside.
- the carbon dioxide microbubble generator may be described as a shower head combined with a carbonated tablet.
- loading or inserting a bathing agent into a shower head means that a tablet is loaded into the carbon dioxide microbubble device, and the bathing agent is placed in the flow path of tap water or tap water to the shower head. It can include loading and use.
- the tablet of the present invention is granulated by a special granulation method and compression-molded to a high hardness, and has excellent foaming properties and is neutral even though it is neutral.
- the gas is vigorously foamed for a long time, generating high-concentration bicarbonate ions and dissolved in hot water. Since the tablet completely neutralizes and removes residual chlorine from the start of dissolution until the completion of dissolution, the blood flow-up effect can be maximized and the warm bath effect can be maximized. Even if the carbonated microbubble generator for loading tablets is in the shower head or set in a part of the hose between the faucet, chlorine can be effectively removed until the end of the tablet dissolution.
- the first and second objects of the present invention are achieved.
- L-ascorbic acid, L-ascorbate represented by sodium L-ascorbate, thiosulfate represented by sodium thiosulfate, sulfite represented by sodium sulfite, erythorbic acid, erythorbate are contained in tap water It is known that it has the ability to neutralize chlorine, but even if these chlorine neutralizing compounds are added to a tablet having a conventional composition, if the tablet is set on a shower head, immediately after the shower is started Although the neutralization ability of chlorine is exerted, the neutralization ability of chlorine is suddenly reduced when the tablet is dissolved by about 1/3 to 1/2, and the neutralization of chlorine is achieved when the tablet is dissolved by 50% or more. The present inventors have found that there are many cases where the ability is lost and the effect of removing chlorine is not exhibited, in relation to the water pressure above a certain level.
- the foaming of carbon dioxide gas occurs stably while being neutral, and the diameter of the foamed carbon dioxide gas can be made into a fine micro-sized bubble having a certain diameter or less.
- Carbon dioxide component is fully dissolved in water and hot water as bicarbonate ions, and after dissolution, the pH of water or hot water is neutral, creating a high concentration bicarbonate spring and percutaneous bicarbonate ions from the skin
- the second object of the present invention is achieved by maximizing absorption, dramatically increasing bicarbonate ions in blood, and maximizing health effects such as blood circulation promotion and body temperature rise.
- the tablet is slowly dissolved over a long period of time by using a tablet having a specific composition or in addition to the tablet hardness regulation and tablet friability regulation. Since the chlorine can be efficiently neutralized and removed throughout the entire dissolution, the second object of the present invention is satisfactorily achieved.
- the present invention has the following effects. Calcium, magnesium, copper and other mineral ions that are ion-bonded to the surface of the scalp and hair proteins, keratin, etc. adhere to the hair roots at a high concentration and accumulate, resulting in hair root mineral stains. Since it is a cation and is ionically bonded to the negative ions of skin and keratin, it cannot be removed by chemical detergents.
- the schematic block diagram which shows one Example (it arrange
- production part The schematic block diagram explaining further another Example (arranged in a shower trunk
- the schematic block diagram explaining further another Example (it arrange
- production part The schematic block diagram explaining further another Example (arranged across the coupling
- production part The schematic block diagram explaining further another Example (it arrange
- the schematic block diagram explaining further another Example (arranged in the middle part of the hose connected to a shower trunk
- production part The schematic block diagram explaining further another Example (arranged in the middle part of the hose connected to a shower trunk
- microbubble mixed water manufacturing method hereinafter sometimes simply referred to as a manufacturing method
- a microbubble mixed water manufacturing device hereinafter also simply referred to as a manufacturing device
- the present invention is a method for producing microbubble mixed water having both a carbonated spring bathing effect and a microbubble effect, and a production device for easily obtaining the microbubble mixed water, and the hot water mixed with carbon dioxide microbubbles is discharged from the production device.
- This is a technique that can be expected to have a health promotion effect such as a cleaning effect and blood circulation promotion by discharging (shower discharge) from (shower discharge port).
- a shower device configured to include a shower head unit 11 having a shower discharge port 13 and a shower body 12 serving as a handle of a handle when used as the manufacturing device 1.
- a shower head unit 11 having a shower discharge port 13 and a shower body 12 serving as a handle of a handle when used as the manufacturing device 1.
- production part 2 which accommodates carbonated bath agent (carbonated spring tablet) T is illustrated. Hot water is supplied to the shower device 10 by the hose 3 connected to the shower body 12.
- drum 12 may be the integral type structure formed integrally, and what was formed separately was connected or couple
- the thing may be used, and the shower head part 11 may be directly or indirectly connected to the shower body part 12 so that the direction and the angle can be changed.
- the micro-bubble generating unit 2 is connected to a water supply device such as a water heater, a water tap, a water supply device, and a hot water tap, which is a water passage 14 between the hot water introduction port 14A and the discharge port 14B.
- a water supply device such as a water heater, a water tap, a water supply device, and a hot water tap, which is a water passage 14 between the hot water introduction port 14A and the discharge port 14B.
- Carbonated bathing agent contained in the microbubble generator 2 by hot water passing through the water passage by being provided at any location in the water supply path from the start end of the hose 3 to be connected to the shower outlet 13. T is dissolved, and the carbon dioxide gas generated by this dissolution becomes microbubbles (fine bubbles) in the hot water and is mixed with the hot water to form microbubble mixed water.
- the microbubble generating unit 2 is configured to have a tablet storage unit 21 provided with a partition structure through which hot water such as a mesh body can pass on the upstream side and the downstream side of the storage position of the carbonated bath agent T. By being disposed in the hot water passage 14, it dissolves by contact with hot water passing through the water passage 14 to generate carbon dioxide, which becomes microbubbles.
- the arrangement position of the microbubble generator 2 is preferably one of the following (1) to (6).
- (1) Configuration arranged in the shower head unit 11 for example, the configuration shown in FIG. 3)
- (2) Configuration arranged in the shower body 12 for example, the configuration shown in FIG. 4)
- the body part side for example, the configuration shown in FIG. 5 of the joint part between the shower head part 11 and the shower body part 12, or the joint part between the shower head part 11 and the shower body part 12 (stretching the joint part)
- FIG. 6 (4) Configuration disposed at the end of the hose 3 connected to the shower body 12 (for example, the configuration shown in FIG.
- the microbubble generator 2 may be built in or incorporated in the terminal portion of the hose 3, or the terminal portion of the hose 2 may be connected to the microbubble generator 2, It is good also as a structure (structure of the Example shown in FIG. 2) which connects the terminal part of the hose 3 to the microbubble generation
- a configuration in which the microbubble generating unit 2 is built in or incorporated in the middle portion of the hose 3 may be used. It is good also as a structure which makes the microbubble generation
- FIG. (5) a configuration in which the microbubble generating unit 2 is built in or incorporated in the middle portion of the hose 3 may be used. It is good also as a structure which makes the microbubble generation
- the tablet container 21 of the microbubble generator 2 can be easily accommodated and added to the carbonated bath agent T according to the configuration in which the tablet container 21 is detachably attached to the shower head 11 and the shower body 12.
- the microbubble generator 2 is not limited to a configuration that is incorporated in the manufacturing device 1 as a part of the components of the manufacturing device 1 as shown in the above embodiment, and is separate from the shower head unit 11 and the shower body 12. It can also be set as the structure, and it can also be set as the structure arrange
- FIG. 1 is a configuration that is incorporated in the manufacturing device 1 as a part of the components of the manufacturing device 1 as shown in the above embodiment, and is separate from the shower head unit 11 and the shower body 12. It can also be set as the structure, and it can also be set as the structure arrange
- the microbubble generator 2 it is easy and quick to store and add the carbonic acid bath agent T by making the microbubble generator 2 an attachment type.
- the carbonic acid bathing agent T accommodated in the microbubble generating part 2 can be visually observed from the outside of the manufacturing device 1. It can also be configured. According to such a configuration, the presence or absence of the carbonic acid bathing agent T accommodated in the microbubble generator 2 and the degree of dissolution can be easily grasped from the outside of the manufacturing device 1.
- the shower head part 11 and / or the shower body part 12 by forming at least a part of the shower head part 11 and / or the shower body part 12 and at least a part of the members constituting the water passage inside the shower head part 11 and / or the shower body part 12, It can also be set as the structure which can visually observe the hot water which flows through the inside of a water passage. According to such a configuration, it is possible to easily grasp whether or not the carbonic acid bathing agent is dissolved in hot water or not, that is, whether or not microbubbles are generated, from the outside of the manufacturing device 1.
- a skin cleanser obtained by solidifying sodium ascorbate is effective in removing chlorine contained in tap water, but when used in a shower bath, the skin cleanser dissolves. In the second half, there was an inconvenience that the chlorine removal effect disappeared.
- the chlorine neutralizing compound is L-ascorbic acid, for example, L-ascorbate represented by sodium L-ascorbate, thiosulfate represented by sodium thiosulfate.
- L-ascorbate represented by sodium L-ascorbate
- thiosulfate represented by sodium thiosulfate.
- Bicarbonate used in the present invention plays a role as a foaming agent, and when dissolved in water (including “hot water” in the present invention, the same shall apply hereinafter) together with an organic acid, While bubbling carbon dioxide in the neutralization reaction, it dissociates into bicarbonate ions and hydrogen ions due to the pH of the dissolved water and dissolves in water. At this time, sodium bicarbonate accelerates the dissolution of the chlorine-neutralized compound represented by sodium L-ascorbate contained together in the tablet with water.
- the content of sodium bicarbonate in the present invention is defined in relation to the mixture B described later containing an organic acid.
- the foaming amount and pH at the time of dissolution in water do not reach the specified values, and not only the effects of the present invention can be exhibited, but also the dissolution of bicarbonate ions in water.
- the amount exceeds the specified value the pH becomes too high, the foaming of carbon dioxide gas is greatly reduced, and the effects of the present invention are hardly exhibited.
- citric acid has a significantly higher reactivity with bicarbonate than succinic acid and malic acid, and neutralizes the sodium bicarbonate. It plays the role of effectively generating carbon dioxide gas, and when it dissolves in water, it also exhibits skin cleaning effects and skin softening effects.
- citric acid, succinic acid, malic acid and fumaric acid are effective as foaming materials as the organic acid, but there are differences in the cosmetic effect as well as the warm bath effect depending on the type of organic acid. Is the best organic acid. The content is specified as described below.
- the content is less than the above, the amount of carbon dioxide foaming decreases while the tablet is dissolved, the amount of dissolved bicarbonate ions decreases, the blood flow enhancement effect etc. decreases, and if the content exceeds the above content
- the foaming amount of carbon dioxide gas increases, but the bubble diameter becomes large and the gas becomes difficult to be neutralized, resulting in a disadvantage that the amount of dissolved bicarbonate ions decreases.
- the salt include sodium salts and calcium salts, but sodium salts are more preferable from the viewpoint of the effects of the present invention.
- L-ascorbic acid is widely known as vitamin C, but when added to tap water, it removes chlorine contained in tap water through the reactions shown in the following reaction formulas 1 and 2.
- Reaction Formula 2 a small amount of hydrochloric acid is generated when chlorine is removed, but the pH of the dissolved water is buffered by the buffer effect of bicarbonate ions and organic acids, and the pH of the shower water and bath water becomes acidic.
- the pH of tap water is stable.
- the content of L-ascorbic acid and L-ascorbate contained in the present invention is less than 0.005 g / 15 g tablet, the ability to remove chlorine may be reduced. When it exceeds, the solidification of the tablet becomes more difficult, and the hardness becomes less than the target.
- the content of other chlorine neutralizing compounds used in the present invention is also preferably in the above range.
- PEG polyethylene glycol
- an organic acid particularly citric acid, succinic acid, malic acid, fumaric acid
- PEG polyethylene glycol
- the mixture of bicarbonate is a granulated material prepared by coating with PEG using a fluidized bed
- the effects of the present invention such as a continuous and uniform reaction in a tablet can be achieved. Expression is greatly exerted.
- the tablet hardness is increased to 15 kg or more, preferably 25 kg or more, particularly preferably 30 kg or more, a continuous and stable reaction of the chlorine neutralizing compound is obtained, and chlorine neutralization inside the tablet is achieved. It is preferable that the part where the tablet is dissolved is suppressed to the reaction and is molded with high hardness so that chlorine can be quickly removed in hot water. The higher the effect of removing chlorine, the greater the effect of promoting blood circulation and increasing health, even when taking a shower.
- the tablet friability of the present invention is 10.0 wt% or less, particularly preferably 5.0 wt% or less, and more preferably 3.0 wt% or less, a continuous and stable reaction of the chlorine neutralizing compound is achieved.
- a continuous and stable reaction of the chlorine neutralizing compound is achieved.
- health promotion effects such as blood circulation promotion and body temperature rise not only when taking a bath in the shower. it can.
- organic acid used in the present invention examples include citric acid, fumaric acid, succinic acid, malic acid and the like.
- citric acid when used as the organic acid, neutralization reaction in the tablet is suppressed and chlorine is removed in hot water.
- the ability can be increased, fine carbon dioxide gas foaming can be realized, and the effect of the present invention can be exhibited more significantly as a preferred compound.
- the reaction can be improved efficiently.
- the powder is fluidized using mechanical blades such as a propeller without using air for stirring. In this case, it does not absorb moisture brought in from humid air during granulation, and can be evacuated with a vacuum pump during granulation, and can be granulated by lowering the amount of PEG. It is preferably used because the effect of extremely reducing the diameter of foaming bubbles can be exhibited while making the reaction more active.
- a mechanical fluidized bed granulator that does not substantially use air as an agitating action is preferably used, and a mixing excavator is arranged in a horizontal drum to cause centrifugal diffusion and vortex action, thereby causing a three-dimensional flow.
- this type of granulator is sold in the market as, for example, a product manufactured by German Radige or a company manufactured by Matsuzaka Giken.
- the granulator is equipped with a vacuum pump for decompressing. That is, the effect of the present invention can be improved by reducing the pressure during cooling and operating so that even a small amount of water can fly.
- a chopper is provided to prevent the granulated granules from becoming coarse particles upon cooling. That is, by operating the chopper at the time of cooling and sizing, the effect of making the diameter of the carbon dioxide bubble in the present invention more micro-sized is exhibited, and this is a more preferable granulation method.
- the most preferable production method is to granulate sodium bicarbonate by a fluidized bed granulator using PEG and a mechanical stirring system, and to the granulated product a certain amount of organic acid, anhydrous sodium carbonate and PEG. After mixing, it is compression molded at high pressure to obtain a tablet.
- the mixture mainly composed of organic acid can also be granulated with PEG, mixed with PEG without granulating bicarbonate, and mixed with organic acid granulated product to obtain tablets.
- the amount of the compound to be granulated is relatively small, and it is a preferable method as a production method from the viewpoint of process. In any case, from the viewpoint of cost, it is desirable to produce by either granulating a bicarbonate or an organic acid and mixing one of them. Chlorine neutralization ability can be seen even if this granulated product is used as a powder, but by compressing it into a single tablet, the neutralization reaction of the present invention is maintained for a long time and the amount of carbon dioxide dissolved is increased. Can be made.
- the PEG used in the present invention is preferably one having an average molecular weight of 1000 to 8000 in view of the effects of the present invention.
- PEG having an average molecular weight of about 4000 to 6000 is particularly preferably PEG6000 from the viewpoint of improvement in molding stability, wrinkle adhesion resistance, capping, tablet molding speed by a compression molding tablet such as a rotary tableting machine,
- the granulation result can be made favorable, and when the tablet is dissolved in hot water, the carbon dioxide component can be dissolved to the maximum in bicarbonate ions.
- the ratio of PEG to 100 parts by weight of the mixture A of bicarbonate (sodium bicarbonate or potassium bicarbonate) (may be granulated product A) is 1/100 to 1/5, particularly preferably 1/100. If the ratio of PEG is less than the above amount, it will be difficult to obtain a sufficiently high hardness, or it will be difficult to obtain a sufficiently low friability, and the diameter of carbon dioxide bubbles will increase, resulting in a foaming time. However, if the amount of PEG is higher than the above, the amount of carbon dioxide bubbles generated is suppressed, and the amount of bicarbonate dissolved in water is the same. The amount of carbonate ions may be reduced.
- the organic acid or the organic acid granulated product B or the PEG organic acid mixture B is added.
- the effect of the present invention can be exhibited more remarkably by adding an anhydride such as, and the effect of increasing the amount of foaming and maintaining it for a long time while making the bubble diameter of carbon dioxide gas small. Is obtained.
- the effect of the present invention can be exhibited more preferably when anhydrous sodium carbonate or anhydrous potassium carbonate is added.
- the organic acid is not granulated, and at least one selected from C6 to C18 alkane sulfonate, olefin acid sulfonate, sucrose fatty acid ester, sodium sulfate, magnesium sulfate and PEG as the organic acid.
- the micro-sized foam of the present invention can be foamed for a long time, and the carbon dioxide component dissolved in the hot water can be increased. A tablet could be obtained. In this case, it is a desirable manufacturing method in which the steps can be greatly omitted and the cost effect is also achieved.
- the organic acid is mixed with PEG and at least one excipient according to the present invention selected from C6-18 alkane sulfonate, olefin acid sulfonate and sucrose fatty acid ester, sodium sulfate, magnesium sulfate, Or when granulated, mixed with the mixture A at a constant temperature and compression molded, the micro-sized foam of the present invention is foamed for a long time, the carbon dioxide component dissolved in water is maximized, and the chlorine removal urine power is stabilized. It was found that a tablet that can be maintained until the end was obtained, which was a desirable production method.
- the ratio of PEG to organic acid used in this production method is preferably 5 to 15 parts by mass with respect to 100 parts by mass of organic acid.
- the addition amount of granulated product B or mixture B to granulated product A or mixture A of bicarbonate is 1/10 It is 0 to 2/3, preferably 1/50 to 2/3, particularly preferably 1/10 to 1/3.
- the organic acid can be added together with PEG or granulated product B and mixed with granulated product A. Then, it is possible to produce a tablet having a preferable neutralization reactivity by tableting by compression molding.
- the anhydrous product is used in any step during compression molding, such as the step of preparing the granulated product A or the mixture A, or the step of mixing the granulated product A with the mixture B or the granulated product B. It is preferable to add a product.
- excipients used for powder mixing and tableting are sodium alkane sulfonate having 6 to 18 carbon atoms, sodium olefin sulfonate having 6 to 18 carbon atoms, sucrose fatty acid ester, sodium sulfate, Such as magnesium sulfate.
- Preferred compounds to be used include sodium n- (normal) octane sulfonate, sodium tetradecene sulfonate, a mixture of sodium C6-C18 alkane sulfonate, sucrose laurate, sucrose myristic ester, sucrose palmitic acid Ester Sodium sulfate Magnesium sulfate is used.
- sodium n- (normal) octane sulfonate, sodium tetradecene sulfonate, and sodium n-heptane sulfonate are particularly preferable for effectively achieving the object of the present invention.
- the amount of sodium n- (normal) octane sulfonate, sodium tetradecene sulfonate and sodium n-heptane sulfonate of the present invention is 1/10 to 1 / with respect to the organic acid used in the tablet according to the present invention.
- the amount is preferably 1000. Similar amounts may be used for other excipients.
- Particularly desirable sodium alkane sulfonate and sodium olefin sulfonate are those containing at least one of a C6 to C18 sodium alkane sulfonate mixture, sodium tetradecene sulfonate and sodium normal octane sulfonate.
- sodium chloride, potassium chloride, dry sodium sulfate, magnesium sulfate, magnesium oxide, anhydrous silicic acid, sodium hydroxide, dextrin, and calcium silicate are additives that exert the effects of the present invention.
- dye, surfactant etc. are mentioned as an additive.
- a known compression molding machine can be used without any particular limitation.
- a hydraulic press machine, a single-shot tablet machine, a rotary tablet machine, a briquetting machine, etc. can be used.
- the size of the punch used in this tableting machine or the like is preferably 7 mm or more when the punch is circular, and when the punch is a triangle or quadrangle, the diameter is 7 mm or more in terms of a circular punch. Those are preferred.
- the tablet diameter is preferably 7 mm or more, more preferably 10 mm or more, and the thickness is also 7 mm or more, preferably 10 mm or more.
- each of the diameter and the thickness is preferably 7 mm or more, particularly preferably 10 mm or more.
- the tablet according to the present invention does not necessarily have a flat shape, and the shape of the tablet is not limited to an oval shape, a so-called tablet shape, or a spherical shape as long as it is a solid body of 7 mm or more.
- the hardness and friability of the present invention and micro-size foaming slowly occur in a tablet of a certain size or more, and more efficiently dissolve carbon dioxide in hot water
- the hardness is 15 kg or more, desirably 25 kg or more, particularly preferably 35 kg or more
- the friability is 10.0 wt% or less, preferably 5 wt% or less, particularly preferably 3 wt% or less
- the diameter or thickness is 10 mm or more.
- the breaking strength of the tablet is measured, and the hardness [kg] of the tablet is measured four times using a digital tablet hardness tester New Speed Checker TS75NL manufactured by Okada Seiko Co., Ltd. as a hardness measurement method in the diameter direction. .
- the hardness was reproducible and no large variation in value was observed.
- the tablet diameter of carbon dioxide gas generated in hot water which is a preferable tablet condition of the present invention
- the tablet diameter is 7 mm or more, particularly 10 mm or more, and it is uniformly generated without bubbles being combined, and neutralization reaction
- the tablet reacts until the tablet is unwound, and the hardness of the tablet is determined using 7 samples of 7 lots of test-produced tablets so that carbon dioxide is neutralized and bicarbonate ions can be efficiently dissolved in hot water. Even if it measured, if it was an average value of 4 times measurement, the fluctuation range of the measured value could be disregarded and it could be confirmed that the tablet had an average hardness of 15 kg or more, particularly 25 kg or more.
- the friability of the tablet according to the present invention will be described.
- the tablets are put in a tablet friability tester (manufactured by Higaki Medical Science Co., Ltd.) so that the tablet weight is 31 g or more.
- the rotation speed is 25 rotations / minute.
- the powder on the surface of each tablet is brushed (worn) with a brush (for example, used for cleaning an analytical balance), and obtained by the following formula.
- Tablet friability Tablet friability (wt%)
- the weight of one tablet is 40 g, 1 tablet is added. When 60 g is used, 1 tablet is also added. When 1 tablet is 16.5 g, 2 tablets are added.
- the friability is 10.0 wt% or less, micro-size foaming in the tablet is caused slowly, and dissolution of carbon dioxide gas in the liquid can be controlled efficiently. Therefore, the friability is 10.0 wt% or less, more preferably 5.0 wt% or less, and particularly preferably 3.0 wt% or less.
- the friability within the present invention is that the generation of carbon dioxide gas in the tablet occurs more efficiently, particularly after dissolution of the tablet starts, the carbon dioxide gas dissolves efficiently in water, and the bubble diameter is reduced. It becomes finer and the effects of the present invention are excellent.
- the reaction may be intense, and the reaction may be terminated in a short time. If the amount of the acid component is too small, the neutralization reaction does not occur efficiently, and the generated carbon dioxide gas is reduced, and the effects of the present invention may not be exhibited.
- the amount of bicarbonate is too small, the amount of PEG used must be increased, otherwise the neutralization reaction will be too intense and the bubble diameter will be increased, impairing the effects of the present invention. Sometimes. Even when the amount of PEG is larger or smaller than the amount of bicarbonate or organic acid, the neutralization reaction may not occur uniformly and continuously, and the bubble diameter may not be constant. .
- a pH adjusting agent that sufficiently exhibits the effects of the present invention is added to adjust the pH in water after dissolution. It is important to make it within the scope of the invention.
- sodium carbonate and organic acid are preferably used, but any other publicly known and publicly available ones can be used without any particular limitation, and in particular, a pH adjuster as a food additive is used. Since tablets may enter the eyes and mouth, it is preferable for safety.
- trisodium citrate sodium citrate
- disodium citrate monosodium citrate
- potassium gluconate sodium gluconate
- examples thereof include disodium succinate, sodium acetate, DL-sodium tartrate, L-sodium tartrate, potassium carbonate, sodium hydrogen carbonate, sodium carbonate, sodium lactate, DL-sodium malate, and the like.
- the present invention is.
- the microbubble maker has a shower head portion and a shower body portion of an integrated configuration or a combined configuration, and the arrangement position of the micro bubble generating portion is any of (1) to (6) above
- the maximum effect of the present invention is exhibited in the case of the microbubble mixed water producing device characterized by being.
- Reference Examples-1 to 3 are listed.
- Operation-1 390 kg of sodium hydrogen carbonate is added to a modified model of RED1200 manufactured by Matsuzaka Giken Co., Ltd., and hot water at 60 ° C. is circulated through the jacket at a rotation speed of 115 rpm.
- the product temperature reaches 55 ° C.
- 20 kg of PEG 6000 is granulated.
- the product temperature reaches 58.5 ° C
- chilled water is circulated through the jacket, the pressure is reduced to 10 torr, and the product temperature is cooled to 45 ° C.
- the obtained granule is called AA granule.
- Operation-2 A 322 kg of AA granules, 69 kg of anhydrous citric acid, 19 kg of anhydrous sodium carbonate, 4.8 kg of PEG 6000, 2.8 kg of sodium L-ascorbate and 2 kg of sodium n-octanesulfonate are added to a modified Leedige mixer VT1200, and 115 minutes at 115 rpm. Stir to make mixture AA.
- Operation-3 Tablet preparation The mixture AA prepared in the above operation was added with 12 tons of weight using a tough press collect 1527HU (tablet making machine) manufactured by Kikusui Seisakusho, and a tablet (1) was prepared with a diameter of 30 mm, a thickness of 12 mm, and a weight of 15 g. .
- the tablet (1) had a hardness of 50 kg and a friability of 3.0 wt%, and the pH of an aqueous solution prepared by dissolving one tablet in 25 ° C. and 1 L of water was 7.00.
- Tablets (1) to (4) were completely dissolved while foaming in about 15 minutes after being put into this hot water.
- Evaluation method 10 subjects (average age: 60.5 years, 5 men and women between 50 and 70 years old) blood flow meter ADVANSALF21N (Blood flow meter from bathing before bathing and 1 hour after bathing) Blood flow was measured using Advanced Co., Ltd. The measurement place is a place on the back side of the hand corresponding to the so-called “Gokukoku”, and measurement was performed with a measurement glove attached to the skin.
- the blood flow measurement pattern is as follows: Resting state: 20 minutes (room temperature 25 ° C) ⁇ Bathing (38 ° C): 20 minutes ⁇ Resting state after bathing (room temperature 25 ° C): 20 minutes 60 minutes total
- the tissue blood flow during bathing measured by the blood flow measurement pattern is shown in FIG. 1 to 38 ° C.
- the present invention of Experiment No. 1 is about 6 times the blood of Experiment No. 5 and about twice the blood of the comparison of Experiments No. 2, 3 and 4. It is clear that the effect of increasing blood flow is clearly sustained even after the end of flow up and bathing. This indicates that the use of the bath agent of the present invention in the state of parasympathetic nerve predominance in low-temperature bathing is very preferable in terms of the effect of increasing blood flow.
- T2-T1 (temperature obtained by subtracting T1 from T2) 10 arithmetic average values increase 5 ... 0.8 ° C or more 4 ... 0.6 or more and less than 0.8 ° C 3 ... 0.4 Above 0.6 ° C rise 2 ... 0.2 or above 0.4 ° C above 1 ... under 0.2
- Evaluation B T3-T2 (temperature obtained by subtracting T2 from T3) has an arithmetic average value of 10 ... 5 less than 0.2 drop 4 ... 0.2 or more and less than 0.4 ° C. 3 ... 0.4 More than 0.6 °C drop 2 ... 0.6 or more less than 0.8 °C drop 1 ... 0.8 °C or more fall
- Example-1 As in Reference Example-1, tablets (21) to (33) were prepared with the compositions shown in Table 4- (2). About these tablets, the experiment at the time of the following shower bath was conducted. Utility model registration No. 3190347 No. 3190347 A tablet is set in the shower head shown in Fig. 1, and a pump that can take a shower of public tap water from a 100L container (a container whose chlorine amount does not change) heated to 40 ° C A device was prepared.
- Residual chlorine concentration in public tap water heated to 40 ° C was measured by JIS K 0102: 2008 33.4 (diphenyl-p-phenylenediammonium (DPD) absorption
- the amount was adjusted to 0.5 mg / L (0.5 ppm) with commercially available sodium hypochlorite while quantifying using a UV-Vis spectrophotometer V-650 manufactured by JASCO Corporation.
- follicle mineral stains are mineral ions such as calcium, magnesium and copper that are ion-bonded to the surface of the scalp and hair proteins, keratin, etc. (ions contained in tap water) ) Is dirt that adheres to and accumulates at a high concentration on the hair root, and is based on visual judgment using a 5-fold magnifier (100% of evaluation 5 was taken as a reference).
- Evaluation 1 The hair root mineral stains are not removed at all.
- Evaluation 2 Less than 20% of follicle mineral stains were removed.
- Evaluation 3 Hair root mineral stain is 20% or more and less than 50%.
- Evaluation 4 50% or more and less than 80% of follicle mineral stains were removed.
- Evaluation 5 80% or more and 100% of hair root mineral stains were removed.
- tablet no. No. 21 was given a new number because the content of the experiment was different even though it had the same composition as tablet (1) of Reference Example-1. same as below.
- Example-2 The sodium n-octanesulfonate in “Operation-2” in Reference Example-1 was replaced with sodium alkanesulfonate having the number of carbon atoms shown in Table 5 below, and the other evaluations were made in the same manner as in Example 1. Table 5- The results are summarized in (1) and Table 5- (2).
- the residual chlorine concentration can be made extremely low from immediately after the start of dissolution of the tablet to immediately before the end of dissolution.
- Table 5- (2) it is understood that the alkanesulfonic acid having 6 to 14 carbon atoms of the present invention is effective in removing hair follicle mineral stain, warming toes after washing, good sleep time and whitening degree. . It can also be seen that a carbon number of 8 or more is more preferable.
- Example-3 Experiment No. 1 of Reference Example-1.
- the amount of citric acid and the amounts of sodium carbonate and sodium bicarbonate were adjusted, and tablets were prepared so as to have a pH as shown in Table 6.
- the weight of 7 tons in Operation-3 was changed as needed to produce tablets with different hardness, and the evaluation results were summarized in Tables 6- (1) and 6- (2).
- the friability was matched with that of Reference Example-1 by changing the maximum loading time of tableting.
- Example-4 Tablets were prepared in the same manner as in Reference Example 1 except that sodium tetradecenesulfonate was used instead of sodium n-octanesulfonate in “Operation-2” in Reference Example-1, and evaluated in the same manner as in Example 1. The results are summarized in Table 7- (1) and Table 7- (2).
- Example-5 Operation-4 Add 306 kg of sodium hydrogen carbonate and 2.8 kg of sodium ascorbate to a modified model of RED1200 manufactured by Matsuzaka Giken, and add 6 to the jacket at 115 rpm. Circulate warm water at 0 ° C, and when the product temperature reaches 55 ° C, add 15.7 kg of PEG6000 and granulate. When the product temperature reaches 58.5 ° C, chilled water is circulated through the jacket, the pressure is reduced to 10 torr, and the product temperature is cooled to 45 ° C. The obtained granule is called BB granule.
- Example-6 Sodium L-ascorbate in “Operation-2” in Reference Example-1 was replaced with sodium sulfite and sodium thiosulfate, and other tablets were prepared in the same manner as in Reference Example-1, and evaluated in the same manner as in Example-1. The results are summarized in Table 9- (1) and Table 9- (2). The friability is 3.0 wt%.
- Citric acid in “Operation-2” in Reference Example-1 was replaced with succinic acid, fumaric acid and malic acid, and the others were prepared in the same manner as in Reference Example-1, evaluated in the same manner as in Example-1, and the results. Are summarized in Table 10- (1) and Table 10- (2).
- Example-8 L-sodium ascorbate in “Operation-2” in Reference Example-1 was changed to potassium ascorbate, calcium ascorbate, erythorbic acid and sodium erythorbate, and n-octanesulfonic acid was changed to C-4 and C-18 alkanesulphonic acid. Except for changing to sodium and sodium lauryl sulfonate (see Table 11), a tablet was prepared in the same manner as in Reference Example 1, and a shower was used in the same manner as in Example 1. The residual chlorine concentration of the shower discharge liquid at the time of 90% consumption and when the tablet was completely dissolved was measured, and the results are summarized in Table 11. The friability was 3.0 wt%. From Table 11 below, it can be seen that the present invention has the effects of the present invention.
- Example-9 Evaluation was conducted in the same manner as in Example-8, except that the mortar and pestle used in Operation-3 of Reference Example-1 were changed and the tablet thickness and tablet diameter were changed as shown in Table 12. The results are summarized in Table 12. The friability was 3.0 wt%. From Table 12 below, only within the scope of the present invention, the residual chlorine concentration can be made extremely low from the start of dissolution of the tablet to the time of complete dissolution.
- the tablet thickness is more preferably 10 mm to 15 mm
- the tablet diameter is more preferably 25 mm to 35 mm.
- Example-10 Experiment No. 1 of Reference Example-1. 1, the weight of 7 tons of operation 3 was changed at any time, tablets with different hardness were prepared, evaluated in the same manner as in Example 9, and the results are summarized in Table 13. However, the friability was set to 3.0 wt% by changing the loading time of the maximum load of tableting.
- the residual chlorine concentration can be made extremely low from the start of dissolution of the tablet to the time of complete dissolution.
- the hardness is preferably 15 kg or more, more preferably 30 kg or more, and most preferably 50 kg or more, to achieve the effects of the present invention.
- Example 11 Experiment No. 1 of Reference Example-1.
- Table 1 tablets with different friability were prepared by changing the tableting speed of 7 tons in operation 3 as needed, and changing the maximum loading time of the tableting tablet particularly by the tableting speed.
- the pH of the dissolved 40 ° C. hot water was 7.0.
- the tablet hardness was set to 50 kg.
- Example-12 In Experiment No. 1 in Reference Example 1, the tableting speed was changed at any time to 7 tons in the operation 3, and the friability was reduced by changing the weighting time of the maximum tableting load especially by the tableting speed. Different tablets were made.
- the pH of the dissolved 40 ° C. hot water was 7.0.
- the tablet hardness was set to 50 kg.
- the effect of the present invention is exhibited when the friability is 10 wt% or less, and the blood flow is improved particularly from the result of (C), and the blood sufficiently flows to the end capillaries to warm the body. I understand that.
- the friability is 5.0 wt% or less
- the effect of the present invention can be further improved.
- the result of (C) shows that the blood flow to the end is improved.
- the effect of the present invention can be best achieved when the content is 3.0 wt% or less, and in particular, the parasympathetic nerve is dominant from the result of (D), and the blood flow is improved, so that the sleep time is the best effect. .
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Cosmetics (AREA)
- Devices For Medical Bathing And Washing (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
しかしながら、その後の実験で本発明者らは炭酸ガス入浴剤や重炭酸イオン入浴剤の血流増進温浴効果は、水道水中の塩素の存在で著しく抑制されてしまうことを見出した。水道水中の塩素など殺菌剤は経皮吸収で自律神経のうち交感神経を一斉に優位にしてしまい
、その結果、副腎皮質からコルチゾールを分泌し血管を収縮させ、血流を低下させてしまう作用があることが判った。これによりシャワーでも温まる、高い温浴効果の炭酸入浴剤や炭酸ガスマイクロバブル発生製造システムを開発しても、塩素の存在がこの効果を台無しにしてしまうという悪作用があり、温浴効果を半減させてしまうことが判った。
また温浴効果だけでなく、塩素は皮膚や毛髪のたんぱく質を破壊する性質を持っているため、塩素が皮膚や毛髪のたんぱく質と反応すれば、皮膚や毛髪を荒らしたり老化させることはもとより、各種の皮膚トラブルの原因となってしまう。また別には皮脂と反応し容易に発がん性のトリハロメタンを生成し癌の発生起因にもなると言われている
ところが本発明者らの実験では、重曹とクエン酸などの有機酸からなる錠剤で、特に特殊な造粒をせずに、硬度も低い従来型の錠剤では、水が浸透することで、錠剤中の塩素中和能力のあるこれら還元性物質を添加しても、水が浸透すると優先的に酸化還元反応を起こしてしまい、錠剤が半分程度溶解した時点で、すでに塩素除去能力を失ってしまうという問題があることが判った。すなわち錠剤に、水が浸透して水が透過浸水すると浸透水が錠剤全体に周り、錠剤が濡れると錠剤中を水が流れるような浸透流が起こり、湯中の塩素が選択的に還元性物質と酸化還元反応を起こしてしまい、錠剤が半分程度溶解した時点で、塩素除去効果が消滅してしまうと欠点が生じることが判明した。特に浴槽での温浴効果が得にくいシャワーでの温浴効果には影響が大きく、炭酸ガスマイクロバブル発生装置内に
未溶解で残っている錠剤の塩素中和除去能力がなくなってしまうことは、シャワーでも血流を上げたいという目的を著しく阻害してしまうことになり、まだ完全な商品とは言えないことが判明した。
湯水の導入口と吐出口との間に設けられたマイクロバブル発生部を有する通水路に導入された湯水と、前記マイクロバブル発生部に収容された炭酸入浴剤を湯水に溶解させて得られるマイクロバブル(微細気泡)とを混合し、
前記吐出口から吐出させて、マイクロバブル混合水を得るマイクロバブル混合水の製造
方法であって、
前記マイクロバブル発生部に収容される炭酸入浴剤は、重炭酸塩、有機酸及びポリエチレングリコールの存在下で圧縮成形した圧縮成形錠剤である炭酸ガスマイクロバブル混合水の製造方法において、
前記炭酸入浴剤は、錠剤直径及び錠剤厚みがそれぞれ7mm以上、錠剤硬度が15kg以上、錠剤摩損度が10wt%以下、該錠剤を湯水に溶かした直後のpHが5.5から9.0である錠剤であり、
かつ前記炭酸入浴剤は、下記賦形剤の少なくとも1つと、下記塩素中和化合物の少なくとも1つを含有することを特徴とする炭酸ガスマイクロバブル混合水の製造方法。
[賦形剤]
炭素数6から18のアルカンスルホン酸塩、炭素数6から18のオレフィンスルホン酸塩、ショ糖脂肪酸エステル、硫酸ナトリウム、硫酸マグネシウム
[塩素中和化合物]
L-アスコルビン酸、L-アスコルビン酸塩、チオ硫酸塩、亜硫酸塩、エリソルビン酸、エリソルビン酸塩
前記賦活剤の含有量は有機酸に対し1/10から1/1000であることを特徴とする、前記発明1に記載の炭酸ガスマイクロバブル混合水の製造方法。
前記塩素中和化合物の含有量は、有機酸に対し8wt%以下であることを特徴とする前記発明1又は2に記載の炭酸ガスマイクロバブル混合水の製造方法。
前記賦活剤が、炭素数6から18のアルカンスルホン酸塩及び炭素数6から18のオレフィンスルホン酸塩であることを特徴とする前記発明1、2又は3に記載の炭酸ガスマイクロバブル混合水の製造方法。
湯水の導入口と吐出口との間に設けられたマイクロバブル発生部を有する通水路に導入された湯水と、前記マイクロバブル発生部に収容された炭酸入浴剤を湯水に溶解させて得られるマイクロバブル(微細気泡)との混合物を、前記吐出口から吐出させてマイクロバブル混合水を得るマイクロバブル混合水の製造器であって、
前記マイクロバブル発生部に収容される炭酸入浴剤は、重炭酸塩、有機酸及びポリエチレングリコールの存在下で圧縮成形した圧縮成形錠剤である炭酸ガスマイクロバブル混合水の製造器において、
前記炭酸入浴剤は、錠剤直径及び錠剤厚みがそれぞれ7mm以上、錠剤硬度が15kg以上、錠剤摩損度が10wt%以下、該錠剤を湯水に溶かした直後のpHが5.5から9.0である錠剤であり、
かつ前記炭酸入浴剤は、下記賦形剤の少なくとも1つと、下記塩素中和化合物の少なくとも1つを含有することを特徴とする炭酸ガスマイクロバブル混合水の製造器。
[賦形剤]
炭素数6から18のアルカンスルホン酸塩、炭素数6から18のオレフィンスルホン酸塩、ショ糖脂肪酸エステル、硫酸ナトリウム、硫酸マグネシウム
[塩素中和化合物]
L-アスコルビン酸、L-アスコルビン酸塩、チオ硫酸塩、亜硫酸塩、エリソルビン酸、エリソルビン酸塩
前記賦活剤の含有量は有機酸に対し1/10から1/1000であることを特徴とする、前記発明5に記載の炭酸ガスマイクロバブル混合水の製造器。
前記塩素中和化合物の含有量は、有機酸に対し8wt%以下であることを特徴とする前記発明5又は6に記載の炭酸ガスマイクロバブル混合水の製造器。
前記賦活剤が、炭素数6から18のアルカンスルホン酸塩及び炭素数6から18のオレフィンスルホン酸塩であることを特徴とする前記発明5、6又は7に記載の炭酸ガスマイクロバブル混合水の製造器。
前記炭酸ガスマイクロバブル混合水の製造器が、一体型構成又は結合型構成のシャワーヘッド部とシャワー胴部とを有し、
前記炭酸ガスマイクロバブル発生部の配設位置が、下記(1)~(6)のいずれかであることを特徴とする前記発明5~8のいずれかに記載の炭酸ガスマイクロバブル混合水の製造器。
(1)シャワーヘッド部に配設される構成
(2)シャワー胴部の中に配設される構成
(3)シャワーヘッド部とシャワー胴部との間、又はシャワーヘッド部とシャワー胴部との結合部乃至は該結合部を跨いで配設される構成
(4)シャワー胴部に接続する送水用のホースの終端部に配設される構成
(5)シャワー胴部に接続する送水用のホースの始端部に配設される構成
(6)シャワー胴部に接続する送水用のホースの中途部に配設される構成
前記炭酸ガスマイクロバブル発生部が、ワンタッチ的な簡易に着脱可能なアタッチメント式であることを特徴とする前記発明5~9のいずれかに記載の炭酸ガスマイクロバブル混合水の製造器。
前記炭酸ガスマイクロバブル発生部が透明性を有する材料で形成され、該炭酸ガスマイクロバブル発生部に収容される炭酸入浴錠剤の溶解状態や錠剤有無が外部から目視可能であることを特徴とする前記発明5~10のいずれかに記載の炭酸ガスマイクロバブル混合水の製造器。
前記炭酸ガスマイクロバブル混合水の製造器の少なくとも一部と、その内部の通水路を構成する部材の少なくとも一部が透明性を有する材料で形成され、外部から通水路内を流れる湯水が目視可能であることを特徴とする前記発明5~11のいずれかに記載の炭酸ガスマイクロバブル混合水の製造器。
なお、本発明において、炭酸ガスマイクロバブル発生装置は炭酸錠剤と組み合わせるシャワーヘッドとも記述する場合がある。またシャワーヘッド内に入浴剤を装填または挿入して用いるとは、炭酸ガスマイクロバブル装置内へ錠剤を装填することを意味し、シャワーヘッドに至る水道水ないし水道湯水の流路中に入浴剤を装填して用いることも含められる。
上記に加え、本発明は次のような作用効果が見られる。
頭皮や毛髪の蛋白質、ケラチン等の表面に付いてイオン結合しているカルシウム、マグネシウム、銅などのミネラルイオンが毛根に高濃度に付着し蓄積して毛根ミネラル汚れとなるが、この毛根ミネラル汚れはカチオンであり皮膚やケラチンのマイナスイオンとイオン結合しているため、化学洗剤ではイオン結合を外せない。そのため、宿根皮脂となっていくら洗っても数時間で臭いが発生する元になっていた。このように合成洗剤型の石鹸やシャンプでのシャワーではこのミネラル皮脂汚れを洗浄することは困難であったが、本発明によれば、フリーの小分子の重炭酸イオンがミネラル皮脂汚れを包接化合物的に取り囲み、洗い流して取り去り、臭いのもとが消えてしまう洗浄効果が毛根の写真撮影から確認されている。それだけでなく、浴槽湯浴や足湯浴では勿論のこと、シャワー入浴であるにも拘らず、脱浴後 数日間は臭いが殆ど消えてしまうことが確認されており、身体の温まり、ぐっすり睡眠効果の増大という本発明の第2の目的以上の美肌・美髪・消臭効果などが確認されている。
マイクロバブル発生部2は、炭酸入浴剤Tの収容位置の上流側及び下流側においてメッシュ体の如き湯水が通過可能な隔壁構成が設けられた錠剤収容部21を有する構成であり、この収容状態で湯水の通水路14内に配設されることによって該通水路14内を通過する湯水との接触により溶解して炭酸ガスを発生し、マイクロバブルとなるものである。
(1)シャワーヘッド部11に配設される構成(例えば、図3に示す構成)
(2)シャワー胴部の中12に配設される構成(例えば、図4に示す構成)
(3)シャワーヘッド部11とシャワー胴部12との結合部の胴部側(例えば、図5に示す構成)、又はシャワーヘッド部11とシャワー胴部12との結合部(該結合部を跨いで配設される構成を含む。例えば、図6に示す構成)
(4)シャワー胴部12に接続するホース3の終端部に配設される構成(例えば、図2に示す構成分)
(5)シャワー胴部12に接続するホース3の始端部に配設される構成(例えば、図7に示す構成)
(6)シャワー胴部12に接続するホース3の中途部に配設される構成(例えば、図8に示す構成)
かかる構成によれば、炭酸入浴剤が湯水に溶解しているか否か又は有無、即ち、マイクロバブルが発生しているか否かを製造器1の外部から容易に把握することができる。
まず、本発明に含まれている成分のうち重炭酸ナトリウムに代表される重炭酸塩を説明する。
低下してしまい、上記含量を超えると、炭酸ガスの発泡量は上がるが 泡の径が大きくなりガスが中和されにくくなり、溶解する重炭酸イオンの量が減少してしまう欠点となる。
C6H8O6 + NaClO → C6H6O6 + H2O + NaCl
(1次殺菌のために投入される次亜塩素酸ナトリウムをアスコルビン酸が還元し除去する反応)
C6H8O6 + Cl2 → C6H6O6 + 2HCl
(塩素濃度の維持のために投入される塩素をアスコルビン酸により除去する反応)
ことができ、好ましい化合物として本発明の効果をより顕著に発揮する。
合物の量が相対的に少なくて済み、工程的な面からの製造方法としては好ましい方法となる。いずれにしろ、コストの面からは重炭酸塩、もしくは有機酸のどちらか一方を造粒し、片方は混合するだけで製造することが望ましい。この造粒物を粉剤のまま使用することでも塩素中和能力は見られるが、圧縮成形して一剤の錠剤とすることで本発明の中和反応を長時間維持し溶解する炭酸ガスを増大させることができる。ただし、重炭酸塩と有機酸の両方をいずれもPEGと混合するかコーテイングして使用することも好ましい製造方法である。
0から2/3、好ましくは1/50から2/3、特に好ましくは1/10から1/3である。
上記、本発明のn-(ノルマル)オクタンスルホン酸ナトリウム、テトラデセンスルホン酸ナトリウム、n-ヘプタンスルホン酸ナトリウムの添加量は、本発明に係る錠剤に用いられる有機酸に対し1/10から1/1000量であることが好ましい。その他の賦形剤の添加量についても同様の量でよい。
そのため硬度は15kg以上、望ましくは25kg以上、特に好ましくは35kg以上であり、また摩損度は10.0wt%以下、好ましくは5wt%以下、特に好ましくは3wt%以下であり、直径や厚みは10mm以上が特に好ましく、錠剤中での炭酸ガスの発生がより効果的に起こり、水中への炭酸ガスの溶解が効率的に行われ、泡の径が細かくなり、本発明の目的を効果的に達成できる。
[(摩損前錠剤重量(g)総和-摩損後の錠剤重量(g)総和)/摩損前錠剤重量(g)総和]×100=錠剤摩損度(wt%)
なお、例えば、1錠の錠剤重量が40gの場合は、1錠入れ、また60gの場合も、1錠入れ、1錠剤が16.5gの場合は、2ケ入れる。
いと、中和反応が激しすぎて泡の径が大きくなり、本発明の効果が損なわれたりする場合がある。また重炭酸塩の量や、有機酸の量に対し、PEGの量が多かったり少なかったりする場合にも、中和反応が均一に持続的に起こらず、泡の径も一定にならない場合がある。
[参考例-1]
操作-1
松坂技研社製レディゲミキサーVT1200改造型に炭酸水素ナトリウム390kgを添加し、回転数115rpmでジャケットに60℃の温水を循環し品温が55℃になったらPEG6000を20kg入れ造粒する。品温が58.5℃になったらジャケットに冷水を循環し、10トールで減圧にし、品温が45℃になるまで冷却する。
得られた顆粒をAA顆粒という。
レディゲミキサーVT1200改良型にAA顆粒322kg、無水クエン酸69kg、無水炭酸ナトリウム19kg、PEG6000を4.8kg、L-アスコルビン酸ナトリウム2.8kg及びn-オクタンスルホン酸ソーダ2kgを入れ、115rpmで10分間攪拌し、混合物AAを作成する。
上記操作で作成した混合物AAを菊水製作所製タフプレスコレクト1527HU(錠剤製造機)により、加重12トンを加え、直径30mm、厚さ12mm、重量15gで錠剤(1)を作成した。この錠剤(1)の硬度は50kg、摩損度3.0wt%であり、1錠を25℃、1Lの水に溶解した水溶液のpHは7.00であった。
評価方法
被験者10名(平均年齢60.5歳、50歳から70歳の男女各5名)で
入浴前から入浴中及び入浴後1時間までの血流測定器レーザードップラー組織血流測定器ADVANSALF21N(株式会社アドバンス製)を用いて血流を測定した。測定場所は、いわゆる「合谷(ごうこく)」に該当する手の背側の個所であり、皮膚に計測グローブを装着して測定した。
血流測定パターンは次の通りである
安静状態:20分(室温25℃)→入浴(38℃):20分→入浴後安静状態(室温25℃):20分
合計60分
図1から38℃という比較的低温の入浴において、実験No.1の本発明は、実験No.5の更湯の約6倍、実験No.2,3及び4の比較の約2倍の血流アップ及び入浴終了後でも血流アップの効果が明らかに持続することが明らかである。
これは、低温入浴における副交感神経優位の状態で、本発明の入浴剤を使用すると、血流アップ効果の点で非常に好ましいことを表している。
[参考例-2]
参考例-1にて作成された錠剤(1)~(4)の他に、参考例-1と同様に錠剤(6)~(14)、(15-1)、(15-2)、(15-3)及び(15-4)を表2に示す組成で作成し、下記のように評価した。
錠剤完全溶解直後、入浴前の足の甲表皮温度(T1)及び20分入浴後の足の甲表皮温度(T2)並びに入浴終了後25℃に空調された部屋で1時間経過後の足の甲表皮温度(T3)を各々測定した。なお、測定は、TO-400非接触赤外線体温計(厚生労働省認可番号226AFBZX00131000)を用いた。
評価A
T2-T1(T2からT1を差し引いた温度)の10人の算術平均値が
5・・・0.8℃以上
4・・・0.6以上0.8℃未満上昇
3・・・0.4以上0.6℃未満上昇
2・・・0.2以上0.4℃未満上
1・・・0.2未満上昇
評価B
T3-T2(T3からT2を差し引いた温度)の10人の算術平均値が
5・・・0.2未満下降
4・・・0.2以上0.4℃未満下降
3・・・0.4以上0.6℃未満下降
2・・・0.6以上0.8℃未満下降
1・・・0.8℃以上下降
[参考例-3]
参考例-1の実験No.1において、操作-3の加重量及び打錠速度を随時変化させて表3に示す摩損度の異なる錠剤(16)~(20)を作製した。これら錠剤(16)~(20)についての、湯水に溶解したpHは、7.0であった。
参考例-2に示すT1、T2及びT3を測定し、評価A及び評価Bの値を求め、その結果を表3に示す。
なお、参考例1~3に示す実験結果は、下記実施例1以下に示すシャワー入浴時の実験でも同様に見られた。
以下、本発明の実施例を挙げる。
[実施例-1]
参考例-1と同様に錠剤(21)~(33)を表4-(2)に示す組成で作成した。これらの錠剤について、下記シャワー入浴時の実験を行った。
実用新案登録第3190347号第1図に示すシャワーヘッドに錠剤をセットし、40℃に加温された100Lの容器(塩素量が変化しない容器)から公共水道水のシャワーを浴びることができるポンプ付き装置を準備した。
この溶液を用いて、錠剤溶解開始直後の、シャワーから出てくるお湯の残留塩素濃度をDPD吸光度法により測定し、その結果を表4-(1)にまとめた。表中の0.05未満は今回の分析に於ける定量下限値未満であることを示している。
錠剤は7分間で溶解し終わる事が確認されたので、溶解終了直前の溶解を開始してから6分30秒後にシャワーから出てくるお湯を採取し、同じくその残留塩素濃度を測定し、その結果を表4-(1)にまとめた。
(B)毛根ミネラル汚れ:「毛根ミネラル汚れ」は、頭皮や毛髪の蛋白質、ケラチン等の表面に付いてイオン結合しているカルシウム、マグネシウム、銅等のミネラルイオン(水道水に含まれているイオン)が高濃度に毛根に付着し蓄積している汚れであり、5倍ルーペを用いた目視判定(評価5の100%取れたが基準)による。
評価1:毛根ミネラル汚れが全く取れていない。
評価2:毛根ミネラル汚れが20%未満取れた。
評価3:毛根ミネラル汚れが20%以上50%未満。
評価4:毛根ミネラル汚れが50%以上80%未満取れた。
評価5:毛根ミネラル汚れが80%以上100%取れた。
評価1:10%未満。
評価2:10%以上20%未満。
評価3:20%以上50%未満。
評価4:50%以上80%未満。
評価5:80%以上100%。
評価1:ぐっすり睡眠時間10%未満。
評価2:ぐっすり睡眠時間10%以上20%未満。
評価3:ぐっすり睡眠時間20%以上40%未満。
評価4:ぐっすり睡眠時間40%以上50%未満。
評価5:ぐっすり睡眠時間50%以上。
評価1:画像全体がくすんでいて透明感がない(透明度0%~20%未満)。
評価2:ほとんどくすんでいて透明感がない(透明度20%以上40%未満)。
評価3:くすみが少なく成り、透明感が出てきた(透明度40%以上60%未満)。
評価4:透明感がある肌として評価される(透明度60%以上80%未満)。
評価5:透明感がある肌でくすみが全くない(透明度80%以上100%)。
上記(B)~(E)の評価結果を表4-(2)にまとめた。
なお、錠剤No.21については、参考例-1の錠剤(1)と同組成分であっても、実験内容が異なるため、新たな番号を付した。以下同じ。
表4-(2)から、本発明の範囲内である場合のみ毛根ミネラル汚れ除去、洗浄後足指の温かさ、ぐっすり睡眠時間及び美白度のいずれにも効果がみられ、一方、本発明範囲外の場合、塩素除去機能が劣り、その他性能評価への影響度が小さいことが明らかである。
参考例-1の「操作-2」におけるn-オクタンスルホン酸ナトリウムを、下記表5に記載の炭素数のアルカンスルホン酸ナトリウムに変え、その他は実施例-1と同様に評価し、表5-(1)及び表5-(2)に結果をまとめた。
表5-(2)から、本発明の炭素数6から14のアルカンスルホン酸は毛根ミネラル汚れ除去、洗浄後足指の温かさ、ぐっすり睡眠時間及び美白度のいずれにも効果がみられることが判る。炭素数は8以上のものがより好ましいことも判る。
参考例-1の実験No.1において、クエン酸量と炭酸ナトリウム及び重炭酸ナトリウムの量を調整し、表6のようなpHとなるように錠剤を作成した。また、操作-3の加重7トンを随時変更し、硬度の異なる錠剤を作成し、表6-(1)及び表6-(2)に評価結果も含めまとめた。ただし、摩損度については、錠剤打錠の最大荷重時間を変化させることにより、参考例-1の摩損度に一致させた。
表6-(2)から、pH5.5からpH8.5が本発明の効果を良く奏し、さらにpH6.2から8.0がより好ましく、6.3から8.0が特に好ましいことが明らかである。硬度は、15kg未満であると本発明の効果にも影響を与えることも判った。なお、pH9.0までが本発明の効果が見られる。
参考例-1の「操作-2」におけるn-オクタンスルホン酸ナトリウムに変え、テトラデセンスルホン酸ナトリウムを使用した他は参考例-1と同様に錠剤を作成し、実施例-1と同様に評価し、表7-(1)及び表7-(2)に結果をまとめた。
表7-(2)から、テトラデセンスルホン酸ナトリウムもアルカンスルホン酸ナトリウムと同様な結果となり、本発明の効果を発揮することが判った。
操作-4
松坂技研社製レディゲミキサーVT1200改造型に炭酸水素ナトリウム306kg及びアスコルビン酸ナトリウム2.8kgを添加し、回転数115rpmでジャケットに6
0℃の温水を循環し、品温が55℃になったらPEG6000を15.7kg入れ造粒する。品温が58.5℃になったらジャケットに冷水を循環し、10トールで減圧にし、品温が45℃になるまで冷却する。
得られた顆粒をBB顆粒という。
レディゲミキサーVT1200改良型にBB顆粒322kg、無水クエン酸69kg、無水炭酸ナトリウム19kg、PEG6000を4.8kg及びn-オクタンスルホン酸ナトリウム2kgを入れ、115rpmで10分間攪拌し、混合物BBを作成する。
上記操作で作成した混合物BBを菊水製作所製タフプレスコレクト1527HU(錠剤製造機)により、加重7トンを加え、直径30mm、厚さ15mm、重量15gで錠剤を作成した。この錠剤の硬度は50kg、摩損度2.4wt%であり、溶解した水溶液(水道水)のpHは7.00であった。
評価は、実施例-1と同様に行い結果を表8-(1)及び表8-(2)に示す。
表8-(2)から、造粒物に入れた場合と混合物に入れた場合で添加量が同じであれば発明の効果も同じであることが判る。
参考例-1の「操作-2」におけるL-アスコルビン酸ナトリウムを、亜硫酸ナトリウム、チオ硫酸ナトリウムに置き換え、その他は参考例-1と同様に錠剤を作成し、実施例-1と同じく評価し、結果を表9-(1)及び表9-(2)にまとめた。なお、摩損度は3.0wt%である。
表9-(2)から、亜硫酸ナトリウム及びチオ硫酸ナトリウムも本発明の効果を奏することが判る。なお、亜硫酸ナトリウムをエリソルビン酸又はエリソルビン酸ナトリウムに置換えた実験も亜硫酸ナトリウムと同様な結果となった。
参考例-1の「操作-2」におけるクエン酸を、コハク酸、フマル酸及びリンゴ酸に置き換え、その他は参考例-1と同様に錠剤を作成し、実施例-1と同じく評価し、結果を表10-(1)及び表10-(2)にまとめた。
表10-(2)から、有機酸の中では、クエン酸が本発明の効果の観点より最も好ましいことが判る。
参考例-1の「操作-2」におけるL-アスコルビン酸ナトリウムをアスコルビン酸カリウム、アスコルビン酸カルシウム、エリソルビン酸及びエリソルビン酸ナトリウムに変え、n-オクタンスルフォン酸をC-4及びC-18アルカンスルフォン酸ナトリウム及びラウリルスルフォン酸ナトリウムに変えた(表11参照)以外は、参考例-1同様に錠剤を作成し、実施例-1同様にシャワーを使用し、錠剤投入時、錠剤50%消費時、錠剤90%消費時及び錠剤完全溶解時のシャワー吐出液の残留塩素濃度を測定し、その結果を表11にまとめた。なお、摩損度は3.0wt%とした。
下記表11から、本発明が、本発明効果を奏していることが判る。
参考例-1の操作―3で使用した臼及び杵を代えて表12のように錠剤厚み及び錠剤径を変化させた以外は、実施例-8と同様に評価した。その結果を表12にまとめた。摩損度は3.0wt%とした。
下記表12から、本発明の範囲内である場合のみ、錠剤の溶解開始直後から完全溶解時まで残留塩素濃度を極めて低濃度にすることができる。
また、本発明の中でも、錠剤厚みは、10mm~15mmがより好ましく、錠剤径は、25mm~35mmがより好ましいことが判った。
参考例-1の実験No.1において、操作3の加重7トンを随時変更し、硬度が異なる錠剤を作成し、実施例9と同様に評価し、結果を表13にまとめた。ただし、錠剤打錠の最大荷重の荷重時間を変化させることによって、摩損度3.0wt%とした。
また、硬度は、好ましくは15kg以上、さらに好ましくは30kg以上、最も好ましくは50kg以上が、本発明の効果を奏することが判る。
参考例-1の実験No.1において、操作3の加重7トンと打錠速度を随時変化させ、特に打錠速度により、錠剤打錠の最大荷重の加重時間を変化させることにより、摩損度が異なる錠剤を作成した。溶解した40℃の湯水のpHは、7.0であった。ただし、錠剤硬度は50kgになるようにした。
参考例-1の実験No.1において、操作3の加重7トンと打錠速度を随時変化させ、特に打錠速度により、錠剤打錠の最大荷重の加重時間を変化させることにより、摩損度が異なる錠剤を作成した。溶解した40℃の湯水のpHは、7.0であった。ただし、錠剤硬度は50kgになるようにした。
判る。摩損度が5.0wt%以下であると本発明の効果をさらに良好に奏することができ、特に(C)の結果により、ますます末端への血流が良くなったことが判る。3.0wt%以下であると本発明の効果を最も良く奏することができ、特に(D)の結果から副交感神経優位となり、血流が向上したことにより、ぐっすり睡眠時間が最高の効果を示した。
Claims (12)
- 湯水の導入口と吐出口との間に設けられたマイクロバブル発生部を有する通水路に導入された湯水と、前記マイクロバブル発生部に収容された炭酸入浴剤を湯水に溶解させて得られるマイクロバブル(微細気泡)とを混合し、
前記吐出口から吐出させて、マイクロバブル混合水を得るマイクロバブル混合水の製造方法であって、
前記マイクロバブル発生部に収容される炭酸入浴剤は、重炭酸塩、有機酸及びポリエチレングリコールの存在下で圧縮成形した圧縮成形錠剤である炭酸ガスマイクロバブル混合水の製造方法において、
前記炭酸入浴剤は、錠剤直径及び錠剤厚みがそれぞれ7mm以上、錠剤硬度が15kg以上、錠剤摩損度が10wt%以下、該錠剤を湯水に溶かした直後のpHが5.5から9.0である錠剤であり、
かつ前記炭酸入浴剤は、下記賦形剤の少なくとも1つと、下記塩素中和化合物の少なくとも1つを含有することを特徴とする炭酸ガスマイクロバブル混合水の製造方法。
[賦形剤]
炭素数6から18のアルカンスルホン酸塩、炭素数6から18のオレフィンスルホン酸塩、ショ糖脂肪酸エステル、硫酸ナトリウム、硫酸マグネシウム
[塩素中和化合物]
L-アスコルビン酸、L-アスコルビン酸塩、チオ硫酸塩、亜硫酸塩、エリソルビン酸、エリソルビン酸塩 - 前記賦活剤の含有量は有機酸に対し1/10から1/1000であることを特徴とする、請求項1に記載の炭酸ガスマイクロバブル混合水の製造方法。
- 前記塩素中和化合物の含有量は、有機酸に対し8wt%以下であることを特徴とする請求項1又は2に記載の炭酸ガスマイクロバブル混合水の製造方法。
- 前記賦活剤が、炭素数6から18のアルカンスルホン酸塩及び炭素数6から18のオレフィンスルホン酸塩であることを特徴とする請求項1、2又は3に記載の炭酸ガスマイクロバブル混合水の製造方法。
- 湯水の導入口と吐出口との間に設けられたマイクロバブル発生部を有する通水路に導入された湯水と、前記マイクロバブル発生部に収容された炭酸入浴剤を湯水に溶解させて得られるマイクロバブル(微細気泡)との混合物を、前記吐出口から吐出させてマイクロバブル混合水を得るマイクロバブル混合水の製造器であって、
前記マイクロバブル発生部に収容される炭酸入浴剤は、重炭酸塩、有機酸及びポリエチレングリコールの存在下で圧縮成形した圧縮成形錠剤である炭酸ガスマイクロバブル混合水の製造器において、
前記炭酸入浴剤は、錠剤直径及び錠剤厚みがそれぞれ7mm以上、錠剤硬度が15kg以上、錠剤摩損度が10wt%以下、該錠剤を湯水に溶かした直後のpHが5.5から9.0である錠剤であり、
かつ前記炭酸入浴剤は、下記賦形剤の少なくとも1つと、下記塩素中和化合物の少なくとも1つを含有することを特徴とする炭酸ガスマイクロバブル混合水の製造器。
[賦形剤]
炭素数6から18のアルカンスルホン酸塩、炭素数6から18のオレフィンスルホン酸塩、ショ糖脂肪酸エステル、硫酸ナトリウム、硫酸マグネシウム
[塩素中和化合物]
L-アスコルビン酸、L-アスコルビン酸塩、チオ硫酸塩、亜硫酸塩、エリソルビン酸、エリソルビン酸塩 - 前記賦活剤の含有量は有機酸に対し1/10から1/1000であることを特徴とする、請求項5に記載の炭酸ガスマイクロバブル混合水の製造器。
- 前記塩素中和化合物の含有量は、有機酸に対し8wt%以下であることを特徴とする請求項5又は6に記載の炭酸ガスマイクロバブル混合水の製造器。
- 前記賦活剤が、炭素数6から18のアルカンスルホン酸塩及び炭素数6から18のオレフィンスルホン酸塩であることを特徴とする請求項5、6又は7に記載の炭酸ガスマイクロバブル混合水の製造器。
- 前記炭酸ガスマイクロバブル混合水の製造器が、一体型構成又は結合型構成のシャワーヘッド部とシャワー胴部とを有し、
前記炭酸ガスマイクロバブル発生部の配設位置が、下記(1)~(6)のいずれかであることを特徴とする請求項5~8のいずれかに記載の炭酸ガスマイクロバブル混合水の製造器。
(1)シャワーヘッド部に配設される構成
(2)シャワー胴部の中に配設される構成
(3)シャワーヘッド部とシャワー胴部との間、又はシャワーヘッド部とシャワー胴部との結合部乃至は該結合部を跨いで配設される構成
(4)シャワー胴部に接続する送水用のホースの終端部に配設される構成
(5)シャワー胴部に接続する送水用のホースの始端部に配設される構成
(6)シャワー胴部に接続する送水用のホースの中途部に配設される構成 - 前記炭酸ガスマイクロバブル発生部が、ワンタッチ的な簡易に着脱可能なアタッチメント式であることを特徴とする請求項5~9のいずれかに記載の炭酸ガスマイクロバブル混合水の製造器。
- 前記炭酸ガスマイクロバブル発生部が透明性を有する材料で形成され、該炭酸ガスマイクロバブル発生部に収容される炭酸入浴錠剤の溶解状態や錠剤有無が外部から目視可能であることを特徴とする請求項5~10のいずれかに記載の炭酸ガスマイクロバブル混合水の製造器。
- 前記炭酸ガスマイクロバブル混合水の製造器の少なくとも一部と、その内部の通水路を構成する部材の少なくとも一部が透明性を有する材料で形成され、外部から通水路内を流れる湯水が目視可能であることを特徴とする請求項5~11のいずれかに記載の炭酸ガスマイクロバブル混合水の製造器。
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020187030781A KR102368817B1 (ko) | 2016-04-07 | 2017-04-06 | 탄산가스 마이크로 버블 혼합수의 제조 방법 및 제조기 |
EP17779195.1A EP3441059A4 (en) | 2016-04-07 | 2017-04-06 | METHOD AND APPARATUS FOR PRODUCING WATER MIXED WITH CARBONIC ACID GAS MICROBULLES |
US16/090,639 US11059000B2 (en) | 2016-04-07 | 2017-04-06 | Method for producing carbon dioxide gas/micro-bubbles mixed water and production device thereof |
JP2017533993A JP6268332B1 (ja) | 2016-04-07 | 2017-04-06 | 炭酸ガスマイクロバブル混合水の製造方法及び製造器 |
CN201780020334.7A CN108883032B (zh) | 2016-04-07 | 2017-04-06 | 二氧化碳微泡混合水的制造方法和制造器 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016-077204 | 2016-04-07 | ||
JP2016077204 | 2016-04-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017175817A1 true WO2017175817A1 (ja) | 2017-10-12 |
Family
ID=60001328
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2017/014317 WO2017175817A1 (ja) | 2016-04-07 | 2017-04-06 | 炭酸ガスマイクロバブル混合水の製造方法及び製造器 |
Country Status (6)
Country | Link |
---|---|
US (1) | US11059000B2 (ja) |
EP (1) | EP3441059A4 (ja) |
JP (4) | JP6668168B2 (ja) |
KR (1) | KR102368817B1 (ja) |
CN (1) | CN108883032B (ja) |
WO (1) | WO2017175817A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019119679A (ja) * | 2017-12-28 | 2019-07-22 | Yoshimoto R&D株式会社 | 化粧品組成物及びその製造方法 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6744890B2 (ja) * | 2018-04-26 | 2020-08-19 | 株式会社ホットアルバム炭酸泉タブレット | マイクロバブル混合水の製造方法及び製造器 |
CA3120203A1 (en) * | 2018-11-15 | 2020-05-22 | 2B1K Imports Pty Ltd | Hair modification system |
CN109316365A (zh) * | 2018-11-29 | 2019-02-12 | 义乌市悦爽生物科技有限公司 | 滋养除氯手霜及其制备方法 |
WO2020210184A1 (en) * | 2019-04-11 | 2020-10-15 | Basf Se | Cleansing tablet |
KR102355395B1 (ko) * | 2019-12-30 | 2022-01-24 | 요시모토 알앤디 가부시키가이샤 | 발포성 화장품 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02255610A (ja) * | 1989-03-29 | 1990-10-16 | Takasugi Seiyaku Kk | 脱塩素型発泡性浴用剤 |
JPH10276926A (ja) * | 1997-04-08 | 1998-10-20 | Toto Ltd | 薬剤徐放機能付シャワーヘッド |
JP2000119161A (ja) | 1998-10-07 | 2000-04-25 | Shoichi Okochi | スキンケア用品あるいは生活用水に皮膚のエージング(老化)抑制または予防効果を付与する方法 |
JP3190347B2 (ja) | 1993-11-29 | 2001-07-23 | 株式会社東レリサーチセンター | 電気泳動分取装置 |
JP2008229516A (ja) | 2007-03-20 | 2008-10-02 | Univ Of Tsukuba | マイクロバブルシャワー |
JP2011194390A (ja) | 2010-03-17 | 2011-10-06 | Kikuchi Eco Earth:Kk | 気液混合装置、気液混合システムおよび気液混合システムを用いた気体成分含有水の製造方法 |
JP2013005861A (ja) * | 2011-06-23 | 2013-01-10 | Nihon Shokuhin Yakka:Kk | シャワーヘッド |
JP2014004317A (ja) | 2012-05-28 | 2014-01-16 | Hot Album Tansansen Tablet Inc | マイクロバブル混合水の製造方法及びマイクロバブル混合水の製造器 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1067374A (zh) * | 1992-05-09 | 1992-12-30 | 宫锡和 | 温泉粉及应用 |
CN1111990A (zh) * | 1994-05-20 | 1995-11-22 | 姜少华 | 含有天然温泉微量元素及植物提取液的沐浴液 |
CN1386494A (zh) * | 2002-06-18 | 2002-12-25 | 李合义 | 一次性矿泉护肤沐浴、洗浴包及其制备方法 |
JP5877778B2 (ja) * | 2012-05-28 | 2016-03-08 | 株式会社ホットアルバム炭酸泉タブレット | 錠剤の製造方法及び錠剤 |
US11058642B2 (en) * | 2013-04-22 | 2021-07-13 | Tower Laboratories Ltd | Tablets with improved friability |
CN104771328A (zh) * | 2015-04-02 | 2015-07-15 | 芜湖美的厨卫电器制造有限公司 | 碳酸泉片剂及其制备方法 |
-
2016
- 2016-06-07 JP JP2016113563A patent/JP6668168B2/ja active Active
- 2016-12-01 JP JP2016233843A patent/JP6525945B2/ja active Active
-
2017
- 2017-04-06 US US16/090,639 patent/US11059000B2/en active Active
- 2017-04-06 KR KR1020187030781A patent/KR102368817B1/ko active IP Right Grant
- 2017-04-06 JP JP2017533993A patent/JP6268332B1/ja active Active
- 2017-04-06 EP EP17779195.1A patent/EP3441059A4/en active Pending
- 2017-04-06 WO PCT/JP2017/014317 patent/WO2017175817A1/ja active Application Filing
- 2017-04-06 CN CN201780020334.7A patent/CN108883032B/zh active Active
- 2017-08-14 JP JP2017156350A patent/JP6534708B2/ja active Active
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02255610A (ja) * | 1989-03-29 | 1990-10-16 | Takasugi Seiyaku Kk | 脱塩素型発泡性浴用剤 |
JP3190347B2 (ja) | 1993-11-29 | 2001-07-23 | 株式会社東レリサーチセンター | 電気泳動分取装置 |
JPH10276926A (ja) * | 1997-04-08 | 1998-10-20 | Toto Ltd | 薬剤徐放機能付シャワーヘッド |
JP2000119161A (ja) | 1998-10-07 | 2000-04-25 | Shoichi Okochi | スキンケア用品あるいは生活用水に皮膚のエージング(老化)抑制または予防効果を付与する方法 |
JP2008229516A (ja) | 2007-03-20 | 2008-10-02 | Univ Of Tsukuba | マイクロバブルシャワー |
JP2011194390A (ja) | 2010-03-17 | 2011-10-06 | Kikuchi Eco Earth:Kk | 気液混合装置、気液混合システムおよび気液混合システムを用いた気体成分含有水の製造方法 |
JP2013005861A (ja) * | 2011-06-23 | 2013-01-10 | Nihon Shokuhin Yakka:Kk | シャワーヘッド |
JP2014004317A (ja) | 2012-05-28 | 2014-01-16 | Hot Album Tansansen Tablet Inc | マイクロバブル混合水の製造方法及びマイクロバブル混合水の製造器 |
Non-Patent Citations (1)
Title |
---|
See also references of EP3441059A4 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019119679A (ja) * | 2017-12-28 | 2019-07-22 | Yoshimoto R&D株式会社 | 化粧品組成物及びその製造方法 |
Also Published As
Publication number | Publication date |
---|---|
JP2018009007A (ja) | 2018-01-18 |
JP6534708B2 (ja) | 2019-06-26 |
JP2017190321A (ja) | 2017-10-19 |
CN108883032A (zh) | 2018-11-23 |
KR20180133868A (ko) | 2018-12-17 |
JP6668168B2 (ja) | 2020-03-18 |
EP3441059A4 (en) | 2019-11-20 |
KR102368817B1 (ko) | 2022-02-28 |
CN108883032B (zh) | 2022-01-11 |
EP3441059A1 (en) | 2019-02-13 |
US20190291061A1 (en) | 2019-09-26 |
US11059000B2 (en) | 2021-07-13 |
JP6525945B2 (ja) | 2019-06-05 |
JP6268332B1 (ja) | 2018-01-24 |
JPWO2017175817A1 (ja) | 2018-04-12 |
JP2017190324A (ja) | 2017-10-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6268332B1 (ja) | 炭酸ガスマイクロバブル混合水の製造方法及び製造器 | |
JP6629806B2 (ja) | 洗顔エステ方法及び洗顔エステ用固形浴剤 | |
JP2014004317A5 (ja) | ||
CN102133155A (zh) | 水溶性良好的皮肤清洗剂 | |
JP6804242B2 (ja) | 頭髪毛根汚れ洗浄用固形洗浄剤及び頭髪毛根汚れ洗浄法 | |
US20180010076A1 (en) | Oxygen-based cleaning composition | |
JP3486114B2 (ja) | 崩壊性粒子 | |
JP6744890B2 (ja) | マイクロバブル混合水の製造方法及び製造器 | |
JP2004002255A (ja) | 粉状沐浴清潔剤及びその調製方法 | |
JP6684251B2 (ja) | シャワー浴兼用の入浴用錠剤の製造方法及びシャワー浴兼用の入浴用錠剤 | |
JP6727249B2 (ja) | マイクロバブル混合水の製造方法及び製造器 | |
JP6462018B2 (ja) | 美容用具セット | |
JP2024075079A (ja) | 炭酸マイクロバブル混合水の製造器及び製造方法 | |
JP6816066B2 (ja) | 足湯温まり方法及び足湯温まりセット | |
JP6764437B2 (ja) | 足湯用長靴形状軟質槽並びに足湯温まり方法及び足湯温まりセット | |
JPH04103524A (ja) | シャワー用浴用剤 | |
JP2023092038A (ja) | 炭酸マイクロバブル混合水の製造器及び製造方法 | |
KR20070040980A (ko) | 발포성 세안 및 목욕 제제 | |
JPH03220119A (ja) | シャワー用浴用剤 | |
JP2001120455A (ja) | シャワー |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref document number: 2017533993 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20187030781 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2017779195 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2017779195 Country of ref document: EP Effective date: 20181107 |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17779195 Country of ref document: EP Kind code of ref document: A1 |